Parkinson's disease (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Parkinson's disease" in English language version.

refsWebsite

Global rank English rank

271nih.gov

4^th place

179doi.org

2^nd place

43semanticscholar.org

11^th place

8^th place

26web.archive.org

1^st place

7worldcat.org

5^th place

7nice.org.uk

3,258^th place

2,666^th place

6parkinson.org

low place

4harvard.edu

18^th place

17^th place

4handle.net

102^nd place

76^th place

4medicines.org.uk

3,823^rd place

2,387^th place

3fda.gov

447^th place

338^th place

2clevelandclinic.org

4,925^th place

3,597^th place

2time.com

61^st place

54^th place

2nytimes.com

7^th place

1books.google.com

3^rd place

1who.int

195^th place

302^nd place

1nhs.uk

1,989^th place

1,528^th place

1ukm.my

low place

1lu.se

4,012^th place

4,295^th place

1bmj.com

1,226^th place

1,421^st place

1exonpublications.com

low place

1unsw.edu.au

4,584^th place

3,029^th place

1zenodo.org

621^st place

380^th place

1artandmedicine.com

low place

1researchgate.net

120^th place

125^th place

1gutenberg.org

489^th place

377^th place

1ufl.edu

921^st place

644^th place

1creativecommons.org

1,010^th place

612^th place

1gsk.com

low place

1pdf.org

low place

1apdaparkinson.org

low place

1epda.eu.com

low place

1michaeljfox.org

low place

1theguardian.com

12^th place

11^th place

1cbsnews.com

108^th place

80^th place

1aan.com

low place

1davisphinneyfoundation.org

low place

1washingtonpost.com

34^th place

27^th place

1scmp.com

362^nd place

245^th place

1cnn.com

28^th place

26^th place

1scientificamerican.com

896^th place

674^th place

1lbda.org

low place

1theconversation.com

928^th place

651^st place

1newscientist.com

774^th place

716^th place

aan.com

Brey RL (April 2006). "Muhammad Ali's Message: Keep Moving Forward". Neurology Now. 2 (2): 8. doi:10.1097/01222928-200602020-00003. Archived from the original on 27 September 2011. Retrieved 22 August 2020.

apdaparkinson.org

"American Parkinson Disease Association: Home". American Parkinson Disease Association. Archived from the original on 10 May 2012. Retrieved 9 August 2010.

artandmedicine.com

"Art and Medicine Bibliography, Paul de Saint-Léger". Art and Medicine. Retrieved 29 April 2023.

bmj.com

jnnp.bmj.com

Jankovic J (April 2008). "Parkinson's disease: clinical features and diagnosis". Journal of Neurology, Neurosurgery, and Psychiatry. 79 (4): 368–376. doi:10.1136/jnnp.2007.131045. PMID 18344392. Archived from the original on 19 August 2015.

books.google.com

Truong & Bhidayasiri 2016, p. 188. Truong DD, Bhidayasiri R (2016). "50: Parkinson's disease". In Lisak RP, Truong DD, Carroll WM, Bhidayasiri R (eds.). International Neurology. John Wiley & Sons. ISBN 978-1-118-77736-7.

cbsnews.com

Burleson N, Breen K (9 November 2023). "Michael J. Fox talks funding breakthrough research for Parkinson's disease". CBS News. Retrieved 23 November 2023.

clevelandclinic.org

my.clevelandclinic.org

"What Is Bradykinesia?". Cleveland Clinic. 30 November 2023. Retrieved 2 May 2024.
"Parkinson's Disease Sleep Problems". Cleveland Clinic. Retrieved 1 May 2024.

cnn.com

Gallman S (4 November 2015). "Robin Williams' widow speaks: Depression didn't kill my husband". CNN. Archived from the original on 4 November 2015. Retrieved 6 April 2018.

creativecommons.org

Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, et al. (2020). "Current and projected future economic burden of Parkinson's disease in the U.S". npj Parkinson's Disease. 6: 15. doi:10.1038/s41531-020-0117-1. PMC 7347582. PMID 32665974. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.

davisphinneyfoundation.org

"Who We Are". Davis Phinney Foundation. Archived from the original on 11 January 2012. Retrieved 18 January 2012.

doi.org

Sveinbjornsdottir S (October 2016). "The clinical symptoms of Parkinson's disease". Journal of Neurochemistry. 139 (Suppl 1): 318–324. doi:10.1111/jnc.13691. PMID 27401947.
Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, et al. (7 December 2021). "Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019". Frontiers in Public Health. 9: 776847. doi:10.3389/fpubh.2021.776847. PMC 8688697. PMID 34950630.
"Correction to Lancet Neurol 2024; 23: 191-204". The Lancet. Neurology. 23 (3): e7. March 2024. doi:10.1016/S1474-4422(24)00048-6. PMID 38365384.
Kon T, Tomiyama M, Wakabayashi K (February 2020). "Neuropathology of Lewy body disease: Clinicopathological crosstalk between typical and atypical cases". Neuropathology. 40 (1): 30–39. doi:10.1111/neup.12597. PMID 31498507. S2CID 201983865.
Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (March 2023). "Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction". Cell Death & Disease. 14 (3): 176. doi:10.1038/s41419-023-05672-9. PMC 9977911. PMID 36859484.
Johansen KK, Torp SH, Farrer MJ, Gustavsson EK, Aasly JO (28 June 2018). "A Case of Parkinson's Disease with No Lewy Body Pathology due to a Homozygous Exon Deletion in Parkin". Case Reports in Neurological Medicine. 2018: 6838965. doi:10.1155/2018/6838965. PMC 6046180. PMID 30050705.
Connie T, Aderinola TB, Ong TS, Goh MKO, Erfianto B, Purnama B (12 December 2022). "Pose-Based Gait Analysis for Diagnosis of Parkinson's Disease". Algorithms. 15 (12). MDPI AG: 474. doi:10.3390/a15120474. ISSN 1999-4893.
Abusrair AH, Elsekaily W, Bohlega S (13 September 2022). "Tremor in Parkinson's Disease: From Pathophysiology to Advanced Therapies". Tremor and Other Hyperkinetic Movements. 12 (1): 29. doi:10.5334/tohm.712. PMC 9504742. PMID 36211804.
Bologna M, Paparella G, Fasano A, Hallett M, Berardelli A (March 2020). "Evolving concepts on bradykinesia". Brain. 143 (3): 727–750. doi:10.1093/brain/awz344. PMC 8205506. PMID 31834375.
Ferreira-Sánchez MD, Moreno-Verdú M, Cano-de-la-Cuerda R (February 2020). "Quantitative Measurement of Rigidity in Parkinson´s Disease: A Systematic Review". Sensors. 20 (3): 880. Bibcode:2020Senso..20..880F. doi:10.3390/s20030880. PMC 7038663. PMID 32041374.
Asci F, Falletti M, Zampogna A, Patera M, Hallett M, Rothwell J, et al. (September 2023). "Rigidity in Parkinson's disease: evidence from biomechanical and neurophysiological measures". Brain. 146 (9): 3705–3718. doi:10.1093/brain/awad114. PMC 10681667. PMID 37018058.
Becker D, Maric A, Schreiner SJ, Büchele F, Baumann CR, Waldvogel D (2 December 2022). Ahmed S (ed.). "Onset of Postural Instability in Parkinson's Disease Depends on Age rather than Disease Duration". Parkinson's Disease. 2022: 6233835. doi:10.1155/2022/6233835. PMC 9734006. PMID 36506486.
Bereczki D (May 2010). "The description of all four cardinal signs of Parkinson's disease in a Hungarian medical text published in 1690". Parkinsonism & Related Disorders. 16 (4): 290–293. doi:10.1016/j.parkreldis.2009.11.006. PMID 19948422.
Eklund M, Nuuttila S, Joutsa J, Jaakkola E, Mäkinen E, Honkanen EA, et al. (July 2022). "Diagnostic value of micrographia in Parkinson's disease: a study with [¹²³I]FP-CIT SPECT". Journal of Neural Transmission. 129 (7): 895–904. doi:10.1007/s00702-022-02517-1. PMC 9217822. PMID 35624405.
Corrà MF, Vila-Chã N, Sardoeira A, Hansen C, Sousa AP, Reis I, et al. (January 2023). "Peripheral neuropathy in Parkinson's disease: prevalence and functional impact on gait and balance". Brain. 146 (1): 225–236. doi:10.1093/brain/awac026. PMC 9825570. PMID 35088837.
França M, Parada Lima J, Oliveira A, Rosas MJ, Vicente SG, Sousa C (September 2023). "Visuospatial memory profile of patients with Parkinson's disease". Applied Neuropsychology. Adult: 1–9. doi:10.1080/23279095.2023.2256918. hdl:10216/141606. PMID 37695259.
Palma JA, Kaufmann H (March 2018). "Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies". Movement Disorders. 33 (3): 372–390. doi:10.1002/mds.27344. PMC 5844369. PMID 29508455.
Warnecke T, Schäfer KH, Claus I, Del Tredici K, Jost WH (March 2022). "Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management". npj Parkinson's Disease. 8 (1): 31. doi:10.1038/s41531-022-00295-x. PMC 8948218. PMID 35332158.
Han MN, Finkelstein DI, McQuade RM, Diwakarla S (January 2022). "Gastrointestinal Dysfunction in Parkinson's Disease: Current and Potential Therapeutics". Journal of Personalized Medicine. 12 (2): 144. doi:10.3390/jpm12020144. PMC 8875119. PMID 35207632.
Skjærbæk C, Knudsen K, Horsager J, Borghammer P (January 2021). "Gastrointestinal Dysfunction in Parkinson's Disease". Journal of Clinical Medicine. 10 (3): 493. doi:10.3390/jcm10030493. PMC 7866791. PMID 33572547.
Palma JA, Kaufmann H (February 2020). "Orthostatic Hypotension in Parkinson Disease". Clinics in Geriatric Medicine. 36 (1): 53–67. doi:10.1016/j.cger.2019.09.002. PMC 7029426. PMID 31733702.
Hinkle JT, Perepezko K, Gonzalez LL, Mills KA, Pontone GM (January 2021). "Apathy and Anxiety in De Novo Parkinson's Disease Predict the Severity of Motor Complications". Movement Disorders Clinical Practice. 8 (1): 76–84. doi:10.1002/mdc3.13117. PMC 7780944. PMID 33426161.
Macías-García P, Rashid-López R, Cruz-Gómez ÁJ, Lozano-Soto E, Sanmartino F, Espinosa-Rosso R, et al. (9 May 2022). Aasly J (ed.). "Neuropsychiatric Symptoms in Clinically Defined Parkinson's Disease: An Updated Review of Literature". Behavioural Neurology. 2022: 1213393. doi:10.1155/2022/1213393. PMC 9110237. PMID 35586201.
Khatri DK, Choudhary M, Sood A, Singh SB (November 2020). "Anxiety: An ignored aspect of Parkinson's disease lacking attention". Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 131: 110776. doi:10.1016/j.biopha.2020.110776. PMID 33152935.
Weintraub D, Mamikonyan E (September 2019). "The Neuropsychiatry of Parkinson Disease: A Perfect Storm". The American Journal of Geriatric Psychiatry. 27 (9): 998–1018. doi:10.1016/j.jagp.2019.03.002. PMC 7015280. PMID 31006550.
Chendo I, Silva C, Duarte GS, Prada L, Voon V, Ferreira JJ (21 January 2022). "Frequency and Characteristics of Psychosis in Parkinson's Disease: A Systematic Review and Meta-Analysis". Journal of Parkinson's Disease. 12 (1): 85–94. doi:10.3233/JPD-212930. PMID 34806620.
Zhang S, Ma Y (September 2022). "Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms". World Journal of Psychiatry. 12 (9): 1127–1140. doi:10.5498/wjp.v12.i9.1127. PMC 9521528. PMID 36186499.
Pahwa R, Isaacson SH, Small GW, Torres-Yaghi Y, Pagan F, Sabbagh M (December 2022). "Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel". Neurology and Therapy. 11 (4): 1571–1582. doi:10.1007/s40120-022-00388-y. PMC 9362468. PMID 35906500.
De Wit LE, Wilting I, Souverein PC, van der Pol P, Egberts TC (May 2022). "Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase". European Neuropsychopharmacology. 58: 30–38. doi:10.1016/j.euroneuro.2022.01.113. PMID 35189453.
Gonzalez-Latapi P, Bayram E, Litvan I, Marras C (May 2021). "Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors". Behavioral Sciences. 11 (5): 74. doi:10.3390/bs11050074. PMC 8152515. PMID 34068064.
Dodet P, Houot M, Leu-Semenescu S, Corvol JC, Lehéricy S, Mangone G, et al. (February 2024). "Sleep disorders in Parkinson's disease, an early and multiple problem". npj Parkinson's Disease. 10 (1): 46. doi:10.1038/s41531-024-00642-0. PMC 10904863. PMID 38424131.
Niemann N, Billnitzer A, Jankovic J (January 2021). "Parkinson's disease and skin". Parkinsonism & Related Disorders. 82: 61–76. doi:10.1016/j.parkreldis.2020.11.017. PMID 33248395.
Almikhlafi MA (January 2024). "A review of the gastrointestinal, olfactory, and skin abnormalities in patients with Parkinson's disease". Neurosciences. 29 (1): 4–9. doi:10.17712/nsj.2024.1.20230062 (inactive 2 May 2024). PMC 10827020. PMID 38195133.{{cite journal}}: CS1 maint: DOI inactive as of May 2024 (link)
Morris HR, Spillantini MG, Sue CM, Williams-Gray CH (January 2024). "The pathogenesis of Parkinson's disease". Lancet. 403 (10423): 293–304. doi:10.1016/s0140-6736(23)01478-2. PMID 38245249.
Coleman C, Martin I (16 December 2022). "Unraveling Parkinson's Disease Neurodegeneration: Does Aging Hold the Clues?". Journal of Parkinson's Disease. 12 (8): 2321–2338. doi:10.3233/JPD-223363. PMC 9837701. PMID 36278358.
De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER (2022). "Preventing Parkinson's Disease: An Environmental Agenda". Journal of Parkinson's Disease. 12 (1): 45–68. doi:10.3233/JPD-212922. PMC 8842749. PMID 34719434. S2CID 240235393.
Zhao Y, Yunjia L, Hilde K (23 April 2024). "Association of Coffee Consumption and Prediagnostic Caffeine Metabolites With Incident Parkinson Disease in a Population-Based Cohort". Neurology. 102 (8): e209201. doi:10.1212/WNL.0000000000209201. PMID 38513162.
Rose KN, Schwarzschild MA, Gomperts SN (February 2024). "Clearing the Smoke: What Protects Smokers from Parkinson's Disease?". Movement Disorders. 39 (2): 267–272. doi:10.1002/mds.29707. PMC 10923097. PMID 38226487.
Salles PA, Tirapegui JM, Chaná-Cuevas P (22 March 2024). "Genetics of Parkinson's disease: Dominant forms and GBA". Neurology Perspectives. 4 (3): 100153. doi:10.1016/j.neurop.2024.100153. ISSN 2667-0496.
Khani M, Cerquera-Cleves C, Kekenadze M, Wild Crea P, Singleton AB, Bandres-Ciga S (May 2024). "Towards a Global View of Parkinson's Disease Genetics". Annals of Neurology. 95 (5): 831–842. doi:10.1002/ana.26905. PMC 11060911. PMID 38557965.
Farrow SL, Gokuladhas S, Schierding W, Pudjihartono M, Perry JK, Cooper AA, et al. (February 2024). "Identification of 27 allele-specific regulatory variants in Parkinson's disease using a massively parallel reporter assay". npj Parkinson's Disease. 10 (1): 44. doi:10.1038/s41531-024-00659-5. PMC 10899198. PMID 38413607.
Smith L, Schapira AH (April 2022). "GBA Variants and Parkinson Disease: Mechanisms and Treatments". Cells. 11 (8): 1261. doi:10.3390/cells11081261. PMC 9029385. PMID 35455941.
Lashuel HA (July 2020). "Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports". Neurobiology of Disease. 141: 104876. doi:10.1016/j.nbd.2020.104876. PMID 32339655.
Abugable AA, Morris JL, Palminha NM, Zaksauskaite R, Ray S, El-Khamisy SF (September 2019). "DNA repair and neurological disease: From molecular understanding to the development of diagnostics and model organisms". DNA Repair. 81: 102669. doi:10.1016/j.dnarep.2019.102669. PMID 31331820.
Santos-Lobato BL (April 2024). "Towards a methodological uniformization of environmental risk studies in Parkinson's disease". npj Parkinson's Disease. 10 (1): 86. doi:10.1038/s41531-024-00709-y. PMC 11024193. PMID 38632283.
Bloem BR, Boonstra TA (December 2023). "The inadequacy of current pesticide regulations for protecting brain health: the case of glyphosate and Parkinson's disease". The Lancet. Planetary Health. 7 (12): e948–e949. doi:10.1016/s2542-5196(23)00255-3. PMID 37949088.
Torrey EF, Simmons W (16 September 2023). "Mercury and Parkinson's Disease: Promising Leads, but Research Is Needed". Parkinson's Disease. 2023: 4709322. doi:10.1155/2023/4709322. PMC 10517869. PMID 37744289.
Zhao Y, Ray A, Portengen L, Vermeulen R, Peters S (July 2023). "Metal Exposure and Risk of Parkinson Disease: A Systematic Review and Meta-Analysis". American Journal of Epidemiology. 192 (7): 1207–1223. doi:10.1093/aje/kwad082. PMC 10326611. PMID 37022311.
Dorsey ER, Zafar M, Lettenberger SE, Pawlik ME, Kinel D, Frissen M, et al. (2023). "Trichloroethylene: An Invisible Cause of Parkinson's Disease?". Journal of Parkinson's Disease. 13 (2): 203–218. doi:10.3233/JPD-225047. PMC 10041423. PMID 36938742.
Kaya I, Nilsson A, Luptáková D, He Y, Vallianatou T, Bjärterot P, et al. (July 2023). "Spatial lipidomics reveals brain region-specific changes of sulfatides in an experimental MPTP Parkinson's disease primate model". npj Parkinson's Disease. 9 (1): 118. doi:10.1038/s41531-023-00558-1. PMC 10372136. PMID 37495571.
Delic V, Beck KD, Pang KC, Citron BA (April 2020). "Biological links between traumatic brain injury and Parkinson's disease". Acta Neuropathologica Communications. 8 (1): 45. doi:10.1186/s40478-020-00924-7. PMC 7137235. PMID 32264976.
Koros C, Simitsi AM, Bougea A, Papagiannakis N, Antonelou R, Pachi I, et al. (July 2023). "Double Trouble: Association of Malignant Melanoma with Sporadic and Genetic Forms of Parkinson's Disease and Asymptomatic Carriers of Related Genes: A Brief Report". Medicina. 59 (8): 1360. doi:10.3390/medicina59081360. PMC 10456316. PMID 37629650.
Fazlollahi A, Zahmatyar M, Alizadeh H, Noori M, Jafari N, Nejadghaderi SA, et al. (October 2022). "Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis". BMC Neurology. 22 (1): 383. doi:10.1186/s12883-022-02874-0. PMC 9552480. PMID 36221048.
Nyholm D, Hellström PM (2 February 2021). "Effects of Helicobacter pylori on Levodopa Pharmacokinetics". Journal of Parkinson's Disease. 11 (1): 61–69. doi:10.3233/JPD-202298. PMC 7990449. PMID 33164946.
Zhou ZD, Yi LX, Wang DQ, Lim TM, Tan EK (September 2023). "Role of dopamine in the pathophysiology of Parkinson's disease". Translational Neurodegeneration. 12 (1): 44. doi:10.1186/s40035-023-00378-6. PMC 10506345. PMID 37718439.
Chen R, Gu X, Wang X (April 2022). "α-Synuclein in Parkinson's disease and advances in detection". Clinica Chimica Acta; International Journal of Clinical Chemistry. 529: 76–86. doi:10.1016/j.cca.2022.02.006. PMID 35176268.
Smida K, Albedah MA, Rashid RF, Al-Qawasmi AR (23 October 2022). "Molecular dynamics method for targeting α-synuclein aggregation induced Parkinson's disease using boron nitride nanostructures". Engineering Analysis with Boundary Elements. 146: 89–95. doi:10.1016/j.enganabound.2022.10.016. ISSN 0955-7997.
Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C, et al. (2008). "Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease". Movement Disorders. 23 (Suppl 3): S548–S559. doi:10.1002/mds.22062. PMID 18781672. S2CID 13186083.
Davie CA (2008). "A review of Parkinson's disease". British Medical Bulletin. 86 (1): 109–127. doi:10.1093/bmb/ldn013. PMID 18398010.
Schulz-Schaeffer WJ (August 2010). "The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia". Acta Neuropathologica. 120 (2): 131–143. doi:10.1007/s00401-010-0711-0. PMC 2892607. PMID 20563819.
Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, et al. (June 2010). "Missing pieces in the Parkinson's disease puzzle". Nature Medicine. 16 (6): 653–661. doi:10.1038/nm.2165. PMID 20495568. S2CID 3146438.
Hirsch EC (December 2009). "Iron transport in Parkinson's disease". Parkinsonism & Related Disorders. 15 (Suppl 3): S209–S211. doi:10.1016/S1353-8020(09)70816-8. PMID 20082992.
Li X, Sundquist J, Sundquist K (23 December 2011). "Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden". Neuro-Degenerative Diseases. 10 (1–4): 277–284. doi:10.1159/000333222. PMID 22205172. S2CID 39874367.
Lai SW, Lin CH, Lin HF, Lin CL, Lin CC, Liao KF (February 2017). "Herpes zoster correlates with increased risk of Parkinson's disease in older people: A population-based cohort study in Taiwan". Medicine. 96 (7): e6075. doi:10.1097/MD.0000000000006075. PMC 5319504. PMID 28207515.
Tan EK, Chao YX, West A, Chan LL, Poewe W, Jankovic J (June 2020). "Parkinson disease and the immune system - associations, mechanisms and therapeutics". Nature Reviews. Neurology. 16 (6): 303–318. doi:10.1038/s41582-020-0344-4. PMID 32332985. S2CID 216111568.
Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, et al. (May 2014). "Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes". Science. 344 (6183): 519–523. Bibcode:2014Sci...344..519R. doi:10.1126/science.1249547. PMC 4910825. PMID 24786080.
Du G, Dong W, Yang Q, Yu X, Ma J, Gu W, et al. (2020). "Altered Gut Microbiota Related to Inflammatory Responses in Patients With Huntington's Disease". Frontiers in Immunology. 11: 603594. doi:10.3389/fimmu.2020.603594. PMC 7933529. PMID 33679692.
Gamborg M, Hvid LG, Dalgas U, Langeskov-Christensen M (3 October 2021). "Review for "Parkinson's disease and intensive exercise therapy — An updated systematic review and meta-analysis"". Acta Neurologica Scandinavica. doi:10.1111/ane.13579/v1/review2. ISSN 1600-0404.
^{[non-primary source needed]}Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. (August 2019). "Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease". Neuron. 103 (4): 627–641.e7. doi:10.1016/j.neuron.2019.05.035. PMC 6706297. PMID 31255487.
Jankovic J (April 2008). "Parkinson's disease: clinical features and diagnosis". Journal of Neurology, Neurosurgery, and Psychiatry. 79 (4): 368–376. doi:10.1136/jnnp.2007.131045. PMID 18344392. Archived from the original on 19 August 2015.
Armstrong MJ, Okun MS (February 2020). "Diagnosis and Treatment of Parkinson Disease: A Review". JAMA. 323 (6): 548–560. doi:10.1001/jama.2019.22360. PMID 32044947. S2CID 211079287.
Poewe W, Wenning G (November 2002). "The differential diagnosis of Parkinson's disease". European Journal of Neurology. 9 (Suppl 3): 23–30. doi:10.1046/j.1468-1331.9.s3.3.x. PMID 12464118.
Gibb WR, Lees AJ (June 1988). "The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry. 51 (6): 745–752. doi:10.1136/jnnp.51.6.745. PMC 1033142. PMID 2841426.
Mustafa HI, Fessel JP, Barwise J, Shannon JR, Raj SR, Diedrich A, et al. (January 2012). "Dysautonomia: perioperative implications". Anesthesiology. 116 (1): 205–215. doi:10.1097/ALN.0b013e31823db712. PMC 3296831. PMID 22143168.
Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G (February 2016). "Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis". Neurology. 86 (6): 566–576. doi:10.1212/WNL.0000000000002350. PMID 26764028. S2CID 207110404.
Brooks DJ (April 2010). "Imaging approaches to Parkinson disease". Journal of Nuclear Medicine. 51 (4): 596–609. doi:10.2967/jnumed.108.059998. PMID 20351351.
Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP (2014). "The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T". PLOS ONE. 9 (4): e93814. Bibcode:2014PLoSO...993814S. doi:10.1371/journal.pone.0093814. PMC 3977922. PMID 24710392.
Mahlknecht P, Krismer F, Poewe W, Seppi K (April 2017). "Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease". Movement Disorders. 32 (4): 619–623. doi:10.1002/mds.26932. PMID 28151553. S2CID 7730034.
Cho SJ, Bae YJ, Kim JM, Kim D, Baik SH, Sunwoo L, et al. (March 2021). "Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis". European Radiology. 31 (3): 1268–1280. doi:10.1007/s00330-020-07240-7. PMID 32886201. S2CID 221478854.
Boonstra JT, Michielse S, Temel Y, Hoogland G, Jahanshahi A (February 2021). "Neuroimaging Detectable Differences between Parkinson's Disease Motor Subtypes: A Systematic Review". Movement Disorders Clinical Practice. 8 (2): 175–192. doi:10.1002/mdc3.13107. PMC 7853198. PMID 33553487.
Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM (2015). "The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review". EJNMMI Research. 5: 12. doi:10.1186/s13550-015-0087-1. PMC 4385258. PMID 25853018.
Greenland & Barker 2018. Greenland JC, Barker RA (2018). "Chapter 6: The Differential Diagnosis of Parkinson's Disease". In Stoker TB, Greenland JC (eds.). Parkinson's disease: Pathogenesis and Clinical Aspects. Codon Publications. pp. 109–128. doi:10.15586/codonpublications.parkinsonsdisease.2018.ch6. ISBN 978-0-9944381-6-4. PMID 30702839. S2CID 80908095.
McCann H, Stevens CH, Cartwright H, Halliday GM (January 2014). "α-Synucleinopathy phenotypes". Parkinsonism & Related Disorders. 20 (Suppl 1): S62–S67. doi:10.1016/S1353-8020(13)70017-8. hdl:1959.4/53593. PMID 24262191.
Ganguly J, Jog M (5 November 2020). "Tauopathy and Movement Disorders-Unveiling the Chameleons and Mimics". Frontiers in Neurology. 11: 599384. doi:10.3389/fneur.2020.599384. PMC 7674803. PMID 33250855.
Gupta D, Kuruvilla A (December 2011). "Vascular parkinsonism: what makes it different?". Postgraduate Medical Journal. 87 (1034): 829–836. doi:10.1136/postgradmedj-2011-130051. PMID 22121251. S2CID 29227069.
Miguel-Puga A, Villafuerte G, Salas-Pacheco J, Arias-Carrión O (22 September 2017). "Therapeutic Interventions for Vascular Parkinsonism: A Systematic Review and Meta-analysis". Frontiers in Neurology. 8: 481. doi:10.3389/fneur.2017.00481. PMC 5614922. PMID 29018399.
Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU (February 2016). "The Differential Diagnosis and Treatment of Atypical Parkinsonism". Deutsches Arzteblatt International. 113 (5): 61–69. doi:10.3238/arztebl.2016.0061. PMC 4782269. PMID 26900156.
Ahlskog JE (July 2011). "Does vigorous exercise have a neuroprotective effect in Parkinson disease?". Neurology. 77 (3): 288–294. doi:10.1212/wnl.0b013e318225ab66. PMC 3136051. PMID 21768599.
Ascherio A, Schwarzschild MA (November 2016). "The epidemiology of Parkinson's disease: risk factors and prevention". The Lancet. Neurology. 15 (12): 1257–1272. doi:10.1016/S1474-4422(16)30230-7. PMID 27751556. S2CID 19994300.
Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A (2010). "Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies". Journal of Alzheimer's Disease. 20 (Suppl 1): S221–S238. doi:10.3233/JAD-2010-091525. PMID 20182023.
de Lau LM, Breteler MM (June 2006). "Epidemiology of Parkinson's disease". The Lancet. Neurology. 5 (6): 525–535. doi:10.1016/S1474-4422(06)70471-9. PMID 16713924. S2CID 39310242.
Kalia LV, Lang AE (August 2015). "Parkinson's disease". Lancet. 386 (9996): 896–912. doi:10.1016/s0140-6736(14)61393-3. PMID 25904081. S2CID 5502904.
Gagne JJ, Power MC (March 2010). "Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis". Neurology. 74 (12): 995–1002. doi:10.1212/WNL.0b013e3181d5a4a3. PMC 2848103. PMID 20308684.
Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS (April 2019). "Emerging therapies in Parkinson disease - repurposed drugs and new approaches". Nature Reviews. Neurology. 15 (4): 204–223. doi:10.1038/s41582-019-0155-7. PMC 7758837. PMID 30867588.
Connolly BS, Lang AE (30 April 2014). "Pharmacological treatment of Parkinson disease: a review". JAMA. 311 (16): 1670–1683. doi:10.1001/jama.2014.3654. PMID 24756517. S2CID 205058847.
Zhang J, Tan LC (2016). "Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist". Current Neuropharmacology. 14 (4): 356–363. doi:10.2174/1570159X14666151208114634. PMC 4876591. PMID 26644151.
Moosa S, Martínez-Fernández R, Elias WJ, Del Alamo M, Eisenberg HM, Fishman PS (September 2019). "The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease". Movement Disorders. 34 (9): 1243–1251. doi:10.1002/mds.27779. PMID 31291491. S2CID 195879250.
Pedrosa DJ, Timmermann L (2013). "Review: management of Parkinson's disease". Neuropsychiatric Disease and Treatment (Review). 9: 321–340. doi:10.2147/NDT.S32302. PMC 3592512. PMID 23487540.
Orgeta V, McDonald KR, Poliakoff E, Hindle JV, Clare L, Leroi I (February 2020). "Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease". The Cochrane Database of Systematic Reviews. 2020 (2): CD011961. doi:10.1002/14651858.cd011961.pub2. PMC 7043362. PMID 32101639.
Dissanayaka 2021, pp. 139–156. Dissanayaka NN (8 March 2021). "Chapter 9: Anxiety in Parkinson's Disease". In Byrne GJ, Panchana NA (eds.). Anxiety in Older People: Clinical and Research Perspectives. Cambridge University Press. pp. 139–156. doi:10.1017/9781139087469.009. ISBN 978-1-108-82636-5. S2CID 87250745.
Oertel WH (13 March 2017). "Recent advances in treating Parkinson's disease". F1000Research (Review). 6: 260. doi:10.12688/f1000research.10100.1. PMC 5357034. PMID 28357055.
Binde et al. 2018, p. missing. Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M (September 2018). "A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease". British Journal of Clinical Pharmacology. 84 (9): 1917–1927. doi:10.1111/bcp.13651. PMC 6089809. PMID 29847694.
Aquino CC, Fox SH (January 2015). "Clinical spectrum of levodopa-induced complications". Movement Disorders. 30 (1): 80–89. doi:10.1002/mds.26125. PMID 25488260. S2CID 22301199.
Yan Z, Wang W, Tao X, Cheng W, Zuo G, Chen Z, et al. (November 2022). "High-dose versus low-dose inhaled levodopa (CVT-301) in patients with Parkinson disease for the treatment of OFF episodes: a meta-analysis of randomized controlled trials". Neurological Sciences. 43 (11): 6233–6241. doi:10.1007/s10072-022-06298-z. PMID 35907110. S2CID 251162631.
Paik J (June 2020). "Levodopa Inhalation Powder: A Review in Parkinson's Disease". Drugs. 80 (8): 821–828. doi:10.1007/s40265-020-01307-x. PMID 32319076. S2CID 216033034.
Tambasco N, Romoli M, Calabresi P (2018). "Levodopa in Parkinson's Disease: Current Status and Future Developments". Current Neuropharmacology. 16 (8): 1239–1252. doi:10.2174/1570159X15666170510143821. PMC 6187751. PMID 28494719.
Akhtar MJ, Yar MS, Grover G, Nath R (January 2020). "Neurological and psychiatric management using COMT inhibitors: A review". Bioorganic Chemistry. 94: 103418. doi:10.1016/j.bioorg.2019.103418. PMID 31708229.
Scott LJ (September 2016). "Opicapone: A Review in Parkinson's Disease". Drugs. 76 (13): 1293–1300. doi:10.1007/s40265-016-0623-y. PMID 27498199. S2CID 5787752.
Samii A, Nutt JG, Ransom BR (May 2004). "Parkinson's disease". Lancet. 363 (9423): 1783–1793. doi:10.1016/S0140-6736(04)16305-8. PMID 15172778. S2CID 35364322.
Ceravolo R, Frosini D, Rossi C, Bonuccelli U (December 2009). "Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management". Parkinsonism & Related Disorders. 15 (Suppl 4): S111–S115. doi:10.1016/S1353-8020(09)70847-8. PMID 20123548.
Binde et al. 2018, p. 1924. Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M (September 2018). "A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease". British Journal of Clinical Pharmacology. 84 (9): 1917–1927. doi:10.1111/bcp.13651. PMC 6089809. PMID 29847694.
Alborghetti M, Nicoletti F (2019). "Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside". Current Neuropharmacology. 17 (9): 861–873. doi:10.2174/1570159X16666180830100754. PMC 7052841. PMID 30160213.
Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, et al. (September 2004). "Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients". BMJ. 329 (7466): 593. doi:10.1136/bmj.38184.606169.AE. PMC 516655. PMID 15310558.
Crosby N, Deane KH, Clarke CE (2003). "Amantadine in Parkinson's disease". The Cochrane Database of Systematic Reviews. 2003 (1): CD003468. doi:10.1002/14651858.CD003468. PMC 8715353. PMID 12535476.
Hasnain M, Vieweg WV, Baron MS, Beatty-Brooks M, Fernandez A, Pandurangi AK (July 2009). "Pharmacological management of psychosis in elderly patients with parkinsonism". The American Journal of Medicine. 122 (7): 614–622. doi:10.1016/j.amjmed.2009.01.025. PMID 19559160.
Elbers RG, Verhoef J, van Wegen EE, Berendse HW, Kwakkel G (October 2015). "Interventions for fatigue in Parkinson's disease". The Cochrane Database of Systematic Reviews (Review). 2015 (10): CD010925. doi:10.1002/14651858.CD010925.pub2. PMC 9240814. PMID 26447539.
Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, et al. (February 2011). "Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues". Archives of Neurology. 68 (2): 165. doi:10.1001/archneurol.2010.260. PMC 4523130. PMID 20937936.
Dallapiazza et al. 2018. Dallapiazza RF, De Vloo PD, Fomenko A, Lee DJ, Hamani C, Munhoz RP, et al. (2018). "Chapter 8: Considerations for Patient and Target Selection in Deep Brain Stimulation surgery for Parkinson's disease". In Stoker TB, Greenland JC (eds.). Parkinson's disease: Pathogenesis and Clinical Aspects. Codon Publications. doi:10.15586/codonpublications.parkinsonsdisease.2018.ch8. ISBN 978-0-9944381-6-4. PMID 30702838. S2CID 81155324.
Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, et al. (Cochrane Movement Disorders Group) (January 2023). "Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis". The Cochrane Database of Systematic Reviews. 1 (1): CD013856. doi:10.1002/14651858.CD013856.pub2. PMC 9815433. PMID 36602886.
Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL (April 2008). "The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis". Movement Disorders. 23 (5): 631–640. doi:10.1002/mds.21922. hdl:10871/17451. PMID 18181210. S2CID 3808899.
Dereli EE, Yaliman A (April 2010). "Comparison of the effects of a physiotherapist-supervised exercise programme and a self-supervised exercise programme on quality of life in patients with Parkinson's disease". Clinical Rehabilitation. 24 (4): 352–362. doi:10.1177/0269215509358933. PMID 20360152. S2CID 10947269.
Jin X, Wang L, Liu S, Zhu L, Loprinzi PD, Fan X (December 2019). "The Impact of Mind-body Exercises on Motor Function, Depressive Symptoms, and Quality of Life in Parkinson's Disease: A Systematic Review and Meta-analysis". International Journal of Environmental Research and Public Health. 17 (1): 31. doi:10.3390/ijerph17010031. PMC 6981975. PMID 31861456.
Barichella M, Cereda E, Pezzoli G (October 2009). "Major nutritional issues in the management of Parkinson's disease". Movement Disorders. 24 (13): 1881–1892. doi:10.1002/mds.22705. hdl:2434/67795. PMID 19691125. S2CID 23528416.
Ramazzina I, Bernazzoli B, Costantino C (31 March 2017). "Systematic review on strength training in Parkinson's disease: an unsolved question". Clinical Interventions in Aging. 12: 619–628. doi:10.2147/CIA.S131903. PMC 5384725. PMID 28408811.
Fox CM, Ramig LO, Ciucci MR, Sapir S, McFarland DH, Farley BG (November 2006). "The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders". Seminars in Speech and Language. 27 (4): 283–299. doi:10.1055/s-2006-955118. PMID 17117354. S2CID 260320960.
Dixon L, Duncan D, Johnson P, Kirkby L, O'Connell H, Taylor H, et al. (July 2007). "Occupational therapy for patients with Parkinson's disease". The Cochrane Database of Systematic Reviews. 2007 (3): CD002813. doi:10.1002/14651858.CD002813.pub2. PMC 6991932. PMID 17636709.
Ferrell B, Connor SR, Cordes A, Dahlin CM, Fine PG, Hutton N, et al. (June 2007). "The national agenda for quality palliative care: the National Consensus Project and the National Quality Forum". Journal of Pain and Symptom Management. 33 (6): 737–744. doi:10.1016/j.jpainsymman.2007.02.024. PMID 17531914.
Lorenzl S, Nübling G, Perrar KM, Voltz R (2013). "Palliative treatment of chronic neurologic disorders". Ethical and Legal Issues in Neurology. Handbook of Clinical Neurology. Vol. 118. Elsevier. pp. 133–139. doi:10.1016/B978-0-444-53501-6.00010-X. ISBN 978-0-444-53501-6. PMID 24182372.
Ghoche R (December 2012). "The conceptual framework of palliative care applied to advanced Parkinson's disease". Parkinsonism & Related Disorders. 18 (Suppl 3): S2–S5. doi:10.1016/j.parkreldis.2012.06.012. PMID 22771241.
Wilcox SK (January 2010). "Extending palliative care to patients with Parkinson's disease". British Journal of Hospital Medicine. 71 (1): 26–30. doi:10.12968/hmed.2010.71.1.45969. PMID 20081638.
Moens K, Higginson IJ, Harding R (October 2014). "Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review". Journal of Pain and Symptom Management. 48 (4): 660–677. doi:10.1016/j.jpainsymman.2013.11.009. PMID 24801658.
Hähnel T, Raschka T, Sapienza S, Klucken J, Glaab E, Corvol JC, et al. (May 2024). "Progression subtypes in Parkinson's disease identified by a data-driven multi cohort analysis". npj Parkinson's Disease. 10 (1): 95. doi:10.1038/s41531-024-00712-3. PMC 11066039. PMID 38698004.
Poewe W (December 2006). "The natural history of Parkinson's disease". Journal of Neurology. 253 (Suppl 7): VII2–VII6. doi:10.1007/s00415-006-7002-7. PMID 17131223. S2CID 35082340.
Sveinbjornsdottir S (October 2016). "The clinical symptoms of Parkinson's disease". Journal of Neurochemistry. 139 (S1): 318–324. doi:10.1111/jnc.13691. PMID 27401947.
Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. (May 2019). "Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016". The Lancet. Neurology. 18 (5): 459–480. doi:10.1016/S1474-4422(18)30499-X. PMC 6459001. PMID 30879893.
Caballol N, Martí MJ, Tolosa E (September 2007). "Cognitive dysfunction and dementia in Parkinson disease". Movement Disorders. 22 (Suppl 17): S358–S366. doi:10.1002/mds.21677. PMID 18175397. S2CID 3229727.
Gomperts SN (April 2016). "Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia". Continuum (Review). 22 (2 Dementia): 435–463. doi:10.1212/CON.0000000000000309. PMC 5390937. PMID 27042903.
Panicker et al. 2021, pp. 1. Panicker N, Ge P, Dawson VL, Dawson TM (April 2021). "The cell biology of Parkinson's disease". The Journal of Cell Biology. 220 (4). doi:10.1083/jcb.202012095. PMC 8103423. PMID 33749710.
Binde et al. 2018, p. 1989. Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M (September 2018). "A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease". British Journal of Clinical Pharmacology. 84 (9): 1917–1927. doi:10.1111/bcp.13651. PMC 6089809. PMID 29847694.
Li G, Ma J, Cui S, He Y, Xiao Q, Liu J, et al. (31 July 2019). "Parkinson's disease in China: a forty-year growing track of bedside work". Translational Neurodegeneration. 8 (1): 22. doi:10.1186/s40035-019-0162-z. PMC 6668186. PMID 31384434.
Dorsey ER, Sherer T, Okun MS, Bloem BR (2018). "The Emerging Evidence of the Parkinson Pandemic". Journal of Parkinson's Disease. 8 (s1): S3–S8. doi:10.3233/JPD-181474. PMC 6311367. PMID 30584159.
Garcia-Ptacek S, Kramberger MG (September 2016). "Parkinson Disease and Dementia". Journal of Geriatric Psychiatry and Neurology. 29 (5): 261–270. doi:10.1177/0891988716654985. PMID 27502301. S2CID 21279235.
Lewis PA, Plun-Favreau H, Rowley M, Spillane J (March 2020). "Pierre D. and the first photographs of Parkinson's disease". Movement Disorders. 35 (3): 389–391. doi:10.1002/MDS.27965. PMC 7155099. PMID 31975439.
Lanska DJ (2009). "Chapter 33 the history of movement disorders". History of Neurology. Handbook of Clinical Neurology. Vol. 95. Elsevier. pp. 501–546. doi:10.1016/S0072-9752(08)02133-7. ISBN 978-0-444-52009-8. PMID 19892136.
Koehler PJ, Keyser A (September 1997). "Tremor in Latin texts of Dutch physicians: 16th-18th centuries". Movement Disorders. 12 (5): 798–806. doi:10.1002/mds.870120531. PMID 9380070. S2CID 310819.
Bereczki D (May 2010). "The description of all four cardinal signs of Parkinson's disease in a Hungarian medical text published in 1690". Parkinsonism & Related Disorders. 16 (4): 290–293. doi:10.1016/j.parkreldis.2009.11.006. PMID 19948422.
Bereczki D, Balla A, Pelok B, Szatmari S (2018). "International recognition of Ferenc Papai Pariz as one of the first descriptors of all 4 cardinal signs of Parkinson's disease". Orvostudományi Értesítő. 91 (1): 60–66. doi:10.2478/orvtudert-2018-0006.
Lees AJ (September 2007). "Unresolved issues relating to the shaking palsy on the celebration of James Parkinson's 250th birthday". Movement Disorders. 22 (Suppl 17): S327–S334. doi:10.1002/mds.21684. PMID 18175393. S2CID 9471754.
Louis ED (November 1997). "The shaking palsy, the first forty-five years: a journey through the British literature". Movement Disorders. 12 (6): 1068–1072. doi:10.1002/mds.870120638. PMID 9399240. S2CID 34630080.
Fahn S (2008). "The history of dopamine and levodopa in the treatment of Parkinson's disease". Movement Disorders. 23 (Suppl 3): S497–S508. doi:10.1002/mds.22028. PMID 18781671. S2CID 45572523.
Guridi J, Lozano AM (November 1997). "A brief history of pallidotomy". Neurosurgery. 41 (5): 1169–1180, discussion 1180–1183. doi:10.1097/00006123-199711000-00029. PMID 9361073.
Hornykiewicz O (2002). "L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent". Amino Acids. 23 (1–3): 65–70. doi:10.1007/s00726-001-0111-9. PMID 12373520. S2CID 25117208.
Coffey RJ (March 2009). "Deep brain stimulation devices: a brief technical history and review". Artificial Organs. 33 (3): 208–220. doi:10.1111/j.1525-1594.2008.00620.x. PMID 18684199.
Armstrong MJ, Okun MS (November 2020). "Time for a New Image of Parkinson Disease". JAMA Neurology. 77 (11): 1345–1346. doi:10.1001/jamaneurol.2020.2412. PMID 32716484. S2CID 220796667.
Prenger MT, Madray R, Van Hedger K, Anello M, MacDonald PA (2020). "Social Symptoms of Parkinson's Disease". Parkinson's Disease. 2020: 8846544. doi:10.1155/2020/8846544. PMC 7790585. PMID 33489081.
Crooks S, Carter G, Wilson CB, Wynne L, Stark P, Doumas M, et al. (2023). "Exploring public perceptions and awareness of Parkinson's disease: A scoping review". PLOS ONE. 18 (9): e0291357. Bibcode:2023PLoSO..1891357C. doi:10.1371/journal.pone.0291357. PMC 10503766. PMID 37713383.
Findley LJ (September 2007). "The economic impact of Parkinson's disease". Parkinsonism & Related Disorders. 13 (Suppl): S8–S12. doi:10.1016/j.parkreldis.2007.06.003. PMID 17702630.
Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, et al. (2020). "Current and projected future economic burden of Parkinson's disease in the U.S". npj Parkinson's Disease. 6: 15. doi:10.1038/s41531-020-0117-1. PMC 7347582. PMID 32665974. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Brey RL (April 2006). "Muhammad Ali's Message: Keep Moving Forward". Neurology Now. 2 (2): 8. doi:10.1097/01222928-200602020-00003. Archived from the original on 27 September 2011. Retrieved 22 August 2020.
Matthews W (April 2006). "Ali's Fighting Spirit". Neurology Now. 2 (2): 10–23. doi:10.1097/01222928-200602020-00004. S2CID 181104230.
Jones JM (December 2004). "Great shakes: famous people with Parkinson disease". Southern Medical Journal. 97 (12): 1186–1189. doi:10.1097/01.SMJ.0000145284.79746.B3. PMID 15646755. S2CID 44340931.
Williams SS (September 2016). "The terrorist inside my husband's brain". Neurology. 87 (13): 1308–1311. doi:10.1212/WNL.0000000000003162. PMID 27672165.
Mari Z, Mestre TA (2022). "The Disease Modification Conundrum in Parkinson's Disease: Failures and Hopes". Frontiers in Aging Neuroscience. 14: 810860. doi:10.3389/fnagi.2022.810860. PMC 8920063. PMID 35296034.
McFarthing K, Rafaloff G, Baptista M, Mursaleen L, Fuest R, Wyse RK, et al. (24 May 2022). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update". Journal of Parkinson's Disease. 12 (4): 1073–1082. doi:10.3233/JPD-229002. PMC 9198738. PMID 35527571.
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. (March 2017). "Parkinson disease". Nature Reviews. Disease Primers. 3 (1): 17013. doi:10.1038/nrdp.2017.13. PMID 28332488. S2CID 11605091.
Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB (October 2019). "Update of the MDS research criteria for prodromal Parkinson's disease". Movement Disorders. 34 (10): 1464–1470. doi:10.1002/mds.27802. PMID 31412427. S2CID 199663713.
Sudhakar V, Richardson RM (January 2019). "Gene Therapy for Neurodegenerative Diseases". Neurotherapeutics. 16 (1): 166–175. doi:10.1007/s13311-018-00694-0. PMC 6361055. PMID 30542906.
Hitti FL, Yang AI, Gonzalez-Alegre P, Baltuch GH (September 2019). "Human gene therapy approaches for the treatment of Parkinson's disease: An overview of current and completed clinical trials". Parkinsonism & Related Disorders. 66: 16–24. doi:10.1016/j.parkreldis.2019.07.018. PMID 31324556. S2CID 198132349.
Volc D, Poewe W, Kutzelnigg A, Lührs P, Thun-Hohenstein C, Schneeberger A, et al. (July 2020). "Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial". The Lancet. Neurology. 19 (7): 591–600. doi:10.1016/S1474-4422(20)30136-8. PMID 32562684. S2CID 219947651.
Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, et al. (October 2018). "Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial". JAMA Neurology. 75 (10): 1206–1214. doi:10.1001/jamaneurol.2018.1487. PMC 6233845. PMID 29913017.
Parmar, Grealish & Henchcliffe 2020, pp. 103. Parmar M, Grealish S, Henchcliffe C (February 2020). "The future of stem cell therapies for Parkinson disease". Nature Reviews. Neuroscience. 21 (2): 103–115. doi:10.1038/s41583-019-0257-7. PMID 31907406.
Parmar, Grealish & Henchcliffe 2020, pp. 103–104. Parmar M, Grealish S, Henchcliffe C (February 2020). "The future of stem cell therapies for Parkinson disease". Nature Reviews. Neuroscience. 21 (2): 103–115. doi:10.1038/s41583-019-0257-7. PMID 31907406.
Parmar, Grealish & Henchcliffe 2020, pp. 106. Parmar M, Grealish S, Henchcliffe C (February 2020). "The future of stem cell therapies for Parkinson disease". Nature Reviews. Neuroscience. 21 (2): 103–115. doi:10.1038/s41583-019-0257-7. PMID 31907406.
Henchcliffe & Parmar 2018, pp. 134. Henchcliffe C, Parmar M (2018). "Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies". Journal of Parkinson's Disease. 8 (s1): S131–S137. doi:10.3233/JPD-181488. PMC 6311366. PMID 30584166.
Parmar, Grealish & Henchcliffe 2020, pp. 106, 108. Parmar M, Grealish S, Henchcliffe C (February 2020). "The future of stem cell therapies for Parkinson disease". Nature Reviews. Neuroscience. 21 (2): 103–115. doi:10.1038/s41583-019-0257-7. PMID 31907406.
Schweitzer JS, Song B, Herrington TM, Park TY, Lee N, Ko S, et al. (May 2020). "Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease". The New England Journal of Medicine. 382 (20): 1926–1932. doi:10.1056/NEJMoa1915872. PMC 7288982. PMID 32402162.
Parmar, Grealish & Henchcliffe 2020, pp. 105, 109. Parmar M, Grealish S, Henchcliffe C (February 2020). "The future of stem cell therapies for Parkinson disease". Nature Reviews. Neuroscience. 21 (2): 103–115. doi:10.1038/s41583-019-0257-7. PMID 31907406.
Henchcliffe & Parmar 2018, pp. 132. Henchcliffe C, Parmar M (2018). "Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies". Journal of Parkinson's Disease. 8 (s1): S131–S137. doi:10.3233/JPD-181488. PMC 6311366. PMID 30584166.
Jenner P (2014). "An overview of adenosine A2A receptor antagonists in Parkinson's disease". International Review of Neurobiology. 119: 71–86. doi:10.1016/B978-0-12-801022-8.00003-9. ISBN 978-0-12-801022-8. PMID 25175961.

epda.eu.com

"About EPDA". European Parkinson's Disease Association. 2010. Archived from the original on 15 August 2010. Retrieved 9 August 2010.

exonpublications.com

Greenland & Barker 2018. Greenland JC, Barker RA (2018). "Chapter 6: The Differential Diagnosis of Parkinson's Disease". In Stoker TB, Greenland JC (eds.). Parkinson's disease: Pathogenesis and Clinical Aspects. Codon Publications. pp. 109–128. doi:10.15586/codonpublications.parkinsonsdisease.2018.ch6. ISBN 978-0-9944381-6-4. PMID 30702839. S2CID 80908095.

fda.gov

"FDA approves first drug to treat hallucinations and delusions associated with Parkinson's disease". www.fda.gov (Press release). 29 April 2016. Retrieved 12 October 2018.
Office of the Commissioner (20 February 2020). "FDA approves new add-on drug to treat off episodes in adults with Parkinson's disease". FDA. Retrieved 23 February 2020.

accessdata.fda.gov

"DaTSCAN Approval Letter" (PDF). FDA.gov. Food and Drug Administration. Retrieved 22 March 2019.

gsk.com

"Parkinson's – 'the shaking palsy'". GlaxoSmithKline. 1 April 2009. Archived from the original on 14 May 2011.

gutenberg.org

Parkinson J (1817). An Essay on the Shaking Palsy. London: Whittingham and Roland for Sherwood, Neely, and Jones. Archived from the original on 24 September 2015.

handle.net

hdl.handle.net

França M, Parada Lima J, Oliveira A, Rosas MJ, Vicente SG, Sousa C (September 2023). "Visuospatial memory profile of patients with Parkinson's disease". Applied Neuropsychology. Adult: 1–9. doi:10.1080/23279095.2023.2256918. hdl:10216/141606. PMID 37695259.
McCann H, Stevens CH, Cartwright H, Halliday GM (January 2014). "α-Synucleinopathy phenotypes". Parkinsonism & Related Disorders. 20 (Suppl 1): S62–S67. doi:10.1016/S1353-8020(13)70017-8. hdl:1959.4/53593. PMID 24262191.
Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL (April 2008). "The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis". Movement Disorders. 23 (5): 631–640. doi:10.1002/mds.21922. hdl:10871/17451. PMID 18181210. S2CID 3808899.
Barichella M, Cereda E, Pezzoli G (October 2009). "Major nutritional issues in the management of Parkinson's disease". Movement Disorders. 24 (13): 1881–1892. doi:10.1002/mds.22705. hdl:2434/67795. PMID 19691125. S2CID 23528416.

harvard.edu

ui.adsabs.harvard.edu

Ferreira-Sánchez MD, Moreno-Verdú M, Cano-de-la-Cuerda R (February 2020). "Quantitative Measurement of Rigidity in Parkinson´s Disease: A Systematic Review". Sensors. 20 (3): 880. Bibcode:2020Senso..20..880F. doi:10.3390/s20030880. PMC 7038663. PMID 32041374.
Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, et al. (May 2014). "Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes". Science. 344 (6183): 519–523. Bibcode:2014Sci...344..519R. doi:10.1126/science.1249547. PMC 4910825. PMID 24786080.
Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP (2014). "The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T". PLOS ONE. 9 (4): e93814. Bibcode:2014PLoSO...993814S. doi:10.1371/journal.pone.0093814. PMC 3977922. PMID 24710392.
Crooks S, Carter G, Wilson CB, Wynne L, Stark P, Doumas M, et al. (2023). "Exploring public perceptions and awareness of Parkinson's disease: A scoping review". PLOS ONE. 18 (9): e0291357. Bibcode:2023PLoSO..1891357C. doi:10.1371/journal.pone.0291357. PMC 10503766. PMID 37713383.

lbda.org

"LBDA Clarifies Autopsy Report on Comedian, Robin Williams". Lewy Body Dementia Association. 10 November 2014. Archived from the original on 12 August 2020. Retrieved 19 April 2018.

lu.se

lup.lub.lu.se

Li X, Sundquist J, Sundquist K (23 December 2011). "Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden". Neuro-Degenerative Diseases. 10 (1–4): 277–284. doi:10.1159/000333222. PMID 22205172. S2CID 39874367.

medicines.org.uk

"Tasmar 100 mg Tablets – Summary of Product Characteristics (SmPC) – (emc)". www.medicines.org.uk. Archived from the original on 6 August 2020. Retrieved 7 January 2021.
"Comtess 200 mg film-coated Tablets – Summary of Product Characteristics (SmPC) – (emc)". www.medicines.org.uk. Retrieved 7 January 2021.
"Stalevo 150 mg/37.5 mg/200 mg Film-coated Tablets – Summary of Product Characteristics (SmPC) – (emc)". www.medicines.org.uk. Retrieved 7 January 2021.
"Ongentys 50 mg hard capsules – Summary of Product Characteristics (SmPC) – (emc)". www.medicines.org.uk. Retrieved 7 January 2021.

michaeljfox.org

"Michael's Story". The Michael J. Fox Foundation for Parkinson's Research. Retrieved 7 May 2023.

newscientist.com

"World's first Parkinson's vaccine is trialled". New Scientist. London. 7 June 2012. Archived from the original on 23 April 2015.

nhs.uk

"Parkinson's disease - Symptoms". National Health Service. 3 November 2022. Retrieved 28 April 2024.

nice.org.uk

guidance.nice.org.uk

The National Collaborating Centre for Chronic Conditions, ed. (2006). "Diagnosing Parkinson's Disease". Parkinson's Disease. London: Royal College of Physicians. pp. 29–47. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.
The National Collaborating Centre for Chronic Conditions, ed. (2006). "Symptomatic pharmacological therapy in Parkinson's disease". Parkinson's Disease (Technical report). London: Royal College of Physicians. pp. 59–100. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010. Retrieved 14 March 2023.
The National Collaborating Centre for Chronic Conditions, ed. (2006). "Palliative care in Parkinson's disease". Parkinson's Disease. London: Royal College of Physicians. pp. 147–151. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.
The National Collaborating Centre for Chronic Conditions, ed. (2006). "Non-motor features of Parkinson's disease". Parkinson's Disease. London: Royal College of Physicians. pp. 113–133. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.
The National Collaborating Centre for Chronic Conditions, ed. (2006). "Surgery for Parkinson's disease". Parkinson's Disease. London: Royal College of Physicians. pp. 101–111. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.
The National Collaborating Centre for Chronic Conditions, ed. (2006). "Other key interventions". Parkinson's Disease. London: Royal College of Physicians. pp. 135–146. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.

nice.org.uk

"Recommendations Parkinson's disease in adults Guidance NICE". NICE. 2006. Retrieved 16 March 2023.

nih.gov

pubmed.ncbi.nlm.nih.gov

Koh J, Ito H (January 2017). "Differential diagnosis of Parkinson's disease and other neurodegenerative disorders". Nihon Rinsho. Japanese Journal of Clinical Medicine. 75 (1): 56–62. PMID 30566295.
Sveinbjornsdottir S (October 2016). "The clinical symptoms of Parkinson's disease". Journal of Neurochemistry. 139 (Suppl 1): 318–324. doi:10.1111/jnc.13691. PMID 27401947.
Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, et al. (7 December 2021). "Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019". Frontiers in Public Health. 9: 776847. doi:10.3389/fpubh.2021.776847. PMC 8688697. PMID 34950630.
"Correction to Lancet Neurol 2024; 23: 191-204". The Lancet. Neurology. 23 (3): e7. March 2024. doi:10.1016/S1474-4422(24)00048-6. PMID 38365384.
Vertes AC, Beato MR, Sonne J, Khan Suheb MZ (June 2023). "Parkinson-Plus Syndrome". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 36256760. Retrieved 2 May 2024.
Kon T, Tomiyama M, Wakabayashi K (February 2020). "Neuropathology of Lewy body disease: Clinicopathological crosstalk between typical and atypical cases". Neuropathology. 40 (1): 30–39. doi:10.1111/neup.12597. PMID 31498507. S2CID 201983865.
Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (March 2023). "Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction". Cell Death & Disease. 14 (3): 176. doi:10.1038/s41419-023-05672-9. PMC 9977911. PMID 36859484.
Johansen KK, Torp SH, Farrer MJ, Gustavsson EK, Aasly JO (28 June 2018). "A Case of Parkinson's Disease with No Lewy Body Pathology due to a Homozygous Exon Deletion in Parkin". Case Reports in Neurological Medicine. 2018: 6838965. doi:10.1155/2018/6838965. PMC 6046180. PMID 30050705.
Abusrair AH, Elsekaily W, Bohlega S (13 September 2022). "Tremor in Parkinson's Disease: From Pathophysiology to Advanced Therapies". Tremor and Other Hyperkinetic Movements. 12 (1): 29. doi:10.5334/tohm.712. PMC 9504742. PMID 36211804.
Bologna M, Paparella G, Fasano A, Hallett M, Berardelli A (March 2020). "Evolving concepts on bradykinesia". Brain. 143 (3): 727–750. doi:10.1093/brain/awz344. PMC 8205506. PMID 31834375.
Ferreira-Sánchez MD, Moreno-Verdú M, Cano-de-la-Cuerda R (February 2020). "Quantitative Measurement of Rigidity in Parkinson´s Disease: A Systematic Review". Sensors. 20 (3): 880. Bibcode:2020Senso..20..880F. doi:10.3390/s20030880. PMC 7038663. PMID 32041374.
Asci F, Falletti M, Zampogna A, Patera M, Hallett M, Rothwell J, et al. (September 2023). "Rigidity in Parkinson's disease: evidence from biomechanical and neurophysiological measures". Brain. 146 (9): 3705–3718. doi:10.1093/brain/awad114. PMC 10681667. PMID 37018058.
Becker D, Maric A, Schreiner SJ, Büchele F, Baumann CR, Waldvogel D (2 December 2022). Ahmed S (ed.). "Onset of Postural Instability in Parkinson's Disease Depends on Age rather than Disease Duration". Parkinson's Disease. 2022: 6233835. doi:10.1155/2022/6233835. PMC 9734006. PMID 36506486.
Bereczki D (May 2010). "The description of all four cardinal signs of Parkinson's disease in a Hungarian medical text published in 1690". Parkinsonism & Related Disorders. 16 (4): 290–293. doi:10.1016/j.parkreldis.2009.11.006. PMID 19948422.
Eklund M, Nuuttila S, Joutsa J, Jaakkola E, Mäkinen E, Honkanen EA, et al. (July 2022). "Diagnostic value of micrographia in Parkinson's disease: a study with [¹²³I]FP-CIT SPECT". Journal of Neural Transmission. 129 (7): 895–904. doi:10.1007/s00702-022-02517-1. PMC 9217822. PMID 35624405.
Corrà MF, Vila-Chã N, Sardoeira A, Hansen C, Sousa AP, Reis I, et al. (January 2023). "Peripheral neuropathy in Parkinson's disease: prevalence and functional impact on gait and balance". Brain. 146 (1): 225–236. doi:10.1093/brain/awac026. PMC 9825570. PMID 35088837.
França M, Parada Lima J, Oliveira A, Rosas MJ, Vicente SG, Sousa C (September 2023). "Visuospatial memory profile of patients with Parkinson's disease". Applied Neuropsychology. Adult: 1–9. doi:10.1080/23279095.2023.2256918. hdl:10216/141606. PMID 37695259.
Palma JA, Kaufmann H (March 2018). "Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies". Movement Disorders. 33 (3): 372–390. doi:10.1002/mds.27344. PMC 5844369. PMID 29508455.
Warnecke T, Schäfer KH, Claus I, Del Tredici K, Jost WH (March 2022). "Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management". npj Parkinson's Disease. 8 (1): 31. doi:10.1038/s41531-022-00295-x. PMC 8948218. PMID 35332158.
Han MN, Finkelstein DI, McQuade RM, Diwakarla S (January 2022). "Gastrointestinal Dysfunction in Parkinson's Disease: Current and Potential Therapeutics". Journal of Personalized Medicine. 12 (2): 144. doi:10.3390/jpm12020144. PMC 8875119. PMID 35207632.
Skjærbæk C, Knudsen K, Horsager J, Borghammer P (January 2021). "Gastrointestinal Dysfunction in Parkinson's Disease". Journal of Clinical Medicine. 10 (3): 493. doi:10.3390/jcm10030493. PMC 7866791. PMID 33572547.
Palma JA, Kaufmann H (February 2020). "Orthostatic Hypotension in Parkinson Disease". Clinics in Geriatric Medicine. 36 (1): 53–67. doi:10.1016/j.cger.2019.09.002. PMC 7029426. PMID 31733702.
Hinkle JT, Perepezko K, Gonzalez LL, Mills KA, Pontone GM (January 2021). "Apathy and Anxiety in De Novo Parkinson's Disease Predict the Severity of Motor Complications". Movement Disorders Clinical Practice. 8 (1): 76–84. doi:10.1002/mdc3.13117. PMC 7780944. PMID 33426161.
Macías-García P, Rashid-López R, Cruz-Gómez ÁJ, Lozano-Soto E, Sanmartino F, Espinosa-Rosso R, et al. (9 May 2022). Aasly J (ed.). "Neuropsychiatric Symptoms in Clinically Defined Parkinson's Disease: An Updated Review of Literature". Behavioural Neurology. 2022: 1213393. doi:10.1155/2022/1213393. PMC 9110237. PMID 35586201.
Khatri DK, Choudhary M, Sood A, Singh SB (November 2020). "Anxiety: An ignored aspect of Parkinson's disease lacking attention". Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 131: 110776. doi:10.1016/j.biopha.2020.110776. PMID 33152935.
Weintraub D, Mamikonyan E (September 2019). "The Neuropsychiatry of Parkinson Disease: A Perfect Storm". The American Journal of Geriatric Psychiatry. 27 (9): 998–1018. doi:10.1016/j.jagp.2019.03.002. PMC 7015280. PMID 31006550.
Chendo I, Silva C, Duarte GS, Prada L, Voon V, Ferreira JJ (21 January 2022). "Frequency and Characteristics of Psychosis in Parkinson's Disease: A Systematic Review and Meta-Analysis". Journal of Parkinson's Disease. 12 (1): 85–94. doi:10.3233/JPD-212930. PMID 34806620.
Zhang S, Ma Y (September 2022). "Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms". World Journal of Psychiatry. 12 (9): 1127–1140. doi:10.5498/wjp.v12.i9.1127. PMC 9521528. PMID 36186499.
Pahwa R, Isaacson SH, Small GW, Torres-Yaghi Y, Pagan F, Sabbagh M (December 2022). "Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel". Neurology and Therapy. 11 (4): 1571–1582. doi:10.1007/s40120-022-00388-y. PMC 9362468. PMID 35906500.
De Wit LE, Wilting I, Souverein PC, van der Pol P, Egberts TC (May 2022). "Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase". European Neuropsychopharmacology. 58: 30–38. doi:10.1016/j.euroneuro.2022.01.113. PMID 35189453.
Gonzalez-Latapi P, Bayram E, Litvan I, Marras C (May 2021). "Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors". Behavioral Sciences. 11 (5): 74. doi:10.3390/bs11050074. PMC 8152515. PMID 34068064.
Bollu PC, Sahota P (2017). "Sleep and Parkinson Disease". Missouri Medicine. 114 (5): 381–386. PMC 6140184. PMID 30228640.
Dodet P, Houot M, Leu-Semenescu S, Corvol JC, Lehéricy S, Mangone G, et al. (February 2024). "Sleep disorders in Parkinson's disease, an early and multiple problem". npj Parkinson's Disease. 10 (1): 46. doi:10.1038/s41531-024-00642-0. PMC 10904863. PMID 38424131.
Niemann N, Billnitzer A, Jankovic J (January 2021). "Parkinson's disease and skin". Parkinsonism & Related Disorders. 82: 61–76. doi:10.1016/j.parkreldis.2020.11.017. PMID 33248395.
Almikhlafi MA (January 2024). "A review of the gastrointestinal, olfactory, and skin abnormalities in patients with Parkinson's disease". Neurosciences. 29 (1): 4–9. doi:10.17712/nsj.2024.1.20230062 (inactive 2 May 2024). PMC 10827020. PMID 38195133.{{cite journal}}: CS1 maint: DOI inactive as of May 2024 (link)
Morris HR, Spillantini MG, Sue CM, Williams-Gray CH (January 2024). "The pathogenesis of Parkinson's disease". Lancet. 403 (10423): 293–304. doi:10.1016/s0140-6736(23)01478-2. PMID 38245249.
Coleman C, Martin I (16 December 2022). "Unraveling Parkinson's Disease Neurodegeneration: Does Aging Hold the Clues?". Journal of Parkinson's Disease. 12 (8): 2321–2338. doi:10.3233/JPD-223363. PMC 9837701. PMID 36278358.
De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER (2022). "Preventing Parkinson's Disease: An Environmental Agenda". Journal of Parkinson's Disease. 12 (1): 45–68. doi:10.3233/JPD-212922. PMC 8842749. PMID 34719434. S2CID 240235393.
Zhao Y, Yunjia L, Hilde K (23 April 2024). "Association of Coffee Consumption and Prediagnostic Caffeine Metabolites With Incident Parkinson Disease in a Population-Based Cohort". Neurology. 102 (8): e209201. doi:10.1212/WNL.0000000000209201. PMID 38513162.
Rose KN, Schwarzschild MA, Gomperts SN (February 2024). "Clearing the Smoke: What Protects Smokers from Parkinson's Disease?". Movement Disorders. 39 (2): 267–272. doi:10.1002/mds.29707. PMC 10923097. PMID 38226487.
Khani M, Cerquera-Cleves C, Kekenadze M, Wild Crea P, Singleton AB, Bandres-Ciga S (May 2024). "Towards a Global View of Parkinson's Disease Genetics". Annals of Neurology. 95 (5): 831–842. doi:10.1002/ana.26905. PMC 11060911. PMID 38557965.
Farrow SL, Gokuladhas S, Schierding W, Pudjihartono M, Perry JK, Cooper AA, et al. (February 2024). "Identification of 27 allele-specific regulatory variants in Parkinson's disease using a massively parallel reporter assay". npj Parkinson's Disease. 10 (1): 44. doi:10.1038/s41531-024-00659-5. PMC 10899198. PMID 38413607.
Smith L, Schapira AH (April 2022). "GBA Variants and Parkinson Disease: Mechanisms and Treatments". Cells. 11 (8): 1261. doi:10.3390/cells11081261. PMC 9029385. PMID 35455941.
Lashuel HA (July 2020). "Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports". Neurobiology of Disease. 141: 104876. doi:10.1016/j.nbd.2020.104876. PMID 32339655.
Abugable AA, Morris JL, Palminha NM, Zaksauskaite R, Ray S, El-Khamisy SF (September 2019). "DNA repair and neurological disease: From molecular understanding to the development of diagnostics and model organisms". DNA Repair. 81: 102669. doi:10.1016/j.dnarep.2019.102669. PMID 31331820.
Santos-Lobato BL (April 2024). "Towards a methodological uniformization of environmental risk studies in Parkinson's disease". npj Parkinson's Disease. 10 (1): 86. doi:10.1038/s41531-024-00709-y. PMC 11024193. PMID 38632283.
Bloem BR, Boonstra TA (December 2023). "The inadequacy of current pesticide regulations for protecting brain health: the case of glyphosate and Parkinson's disease". The Lancet. Planetary Health. 7 (12): e948–e949. doi:10.1016/s2542-5196(23)00255-3. PMID 37949088.
Torrey EF, Simmons W (16 September 2023). "Mercury and Parkinson's Disease: Promising Leads, but Research Is Needed". Parkinson's Disease. 2023: 4709322. doi:10.1155/2023/4709322. PMC 10517869. PMID 37744289.
Zhao Y, Ray A, Portengen L, Vermeulen R, Peters S (July 2023). "Metal Exposure and Risk of Parkinson Disease: A Systematic Review and Meta-Analysis". American Journal of Epidemiology. 192 (7): 1207–1223. doi:10.1093/aje/kwad082. PMC 10326611. PMID 37022311.
Dorsey ER, Zafar M, Lettenberger SE, Pawlik ME, Kinel D, Frissen M, et al. (2023). "Trichloroethylene: An Invisible Cause of Parkinson's Disease?". Journal of Parkinson's Disease. 13 (2): 203–218. doi:10.3233/JPD-225047. PMC 10041423. PMID 36938742.
Kaya I, Nilsson A, Luptáková D, He Y, Vallianatou T, Bjärterot P, et al. (July 2023). "Spatial lipidomics reveals brain region-specific changes of sulfatides in an experimental MPTP Parkinson's disease primate model". npj Parkinson's Disease. 9 (1): 118. doi:10.1038/s41531-023-00558-1. PMC 10372136. PMID 37495571.
Delic V, Beck KD, Pang KC, Citron BA (April 2020). "Biological links between traumatic brain injury and Parkinson's disease". Acta Neuropathologica Communications. 8 (1): 45. doi:10.1186/s40478-020-00924-7. PMC 7137235. PMID 32264976.
Koros C, Simitsi AM, Bougea A, Papagiannakis N, Antonelou R, Pachi I, et al. (July 2023). "Double Trouble: Association of Malignant Melanoma with Sporadic and Genetic Forms of Parkinson's Disease and Asymptomatic Carriers of Related Genes: A Brief Report". Medicina. 59 (8): 1360. doi:10.3390/medicina59081360. PMC 10456316. PMID 37629650.
Fazlollahi A, Zahmatyar M, Alizadeh H, Noori M, Jafari N, Nejadghaderi SA, et al. (October 2022). "Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis". BMC Neurology. 22 (1): 383. doi:10.1186/s12883-022-02874-0. PMC 9552480. PMID 36221048.
Nyholm D, Hellström PM (2 February 2021). "Effects of Helicobacter pylori on Levodopa Pharmacokinetics". Journal of Parkinson's Disease. 11 (1): 61–69. doi:10.3233/JPD-202298. PMC 7990449. PMID 33164946.
Zhou ZD, Yi LX, Wang DQ, Lim TM, Tan EK (September 2023). "Role of dopamine in the pathophysiology of Parkinson's disease". Translational Neurodegeneration. 12 (1): 44. doi:10.1186/s40035-023-00378-6. PMC 10506345. PMID 37718439.
Chen R, Gu X, Wang X (April 2022). "α-Synuclein in Parkinson's disease and advances in detection". Clinica Chimica Acta; International Journal of Clinical Chemistry. 529: 76–86. doi:10.1016/j.cca.2022.02.006. PMID 35176268.
Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C, et al. (2008). "Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease". Movement Disorders. 23 (Suppl 3): S548–S559. doi:10.1002/mds.22062. PMID 18781672. S2CID 13186083.
Davie CA (2008). "A review of Parkinson's disease". British Medical Bulletin. 86 (1): 109–127. doi:10.1093/bmb/ldn013. PMID 18398010.
Schulz-Schaeffer WJ (August 2010). "The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia". Acta Neuropathologica. 120 (2): 131–143. doi:10.1007/s00401-010-0711-0. PMC 2892607. PMID 20563819.
Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, et al. (June 2010). "Missing pieces in the Parkinson's disease puzzle". Nature Medicine. 16 (6): 653–661. doi:10.1038/nm.2165. PMID 20495568. S2CID 3146438.
Hirsch EC (December 2009). "Iron transport in Parkinson's disease". Parkinsonism & Related Disorders. 15 (Suppl 3): S209–S211. doi:10.1016/S1353-8020(09)70816-8. PMID 20082992.
Li X, Sundquist J, Sundquist K (23 December 2011). "Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden". Neuro-Degenerative Diseases. 10 (1–4): 277–284. doi:10.1159/000333222. PMID 22205172. S2CID 39874367.
Lai SW, Lin CH, Lin HF, Lin CL, Lin CC, Liao KF (February 2017). "Herpes zoster correlates with increased risk of Parkinson's disease in older people: A population-based cohort study in Taiwan". Medicine. 96 (7): e6075. doi:10.1097/MD.0000000000006075. PMC 5319504. PMID 28207515.
Tan EK, Chao YX, West A, Chan LL, Poewe W, Jankovic J (June 2020). "Parkinson disease and the immune system - associations, mechanisms and therapeutics". Nature Reviews. Neurology. 16 (6): 303–318. doi:10.1038/s41582-020-0344-4. PMID 32332985. S2CID 216111568.
Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, et al. (May 2014). "Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes". Science. 344 (6183): 519–523. Bibcode:2014Sci...344..519R. doi:10.1126/science.1249547. PMC 4910825. PMID 24786080.
Du G, Dong W, Yang Q, Yu X, Ma J, Gu W, et al. (2020). "Altered Gut Microbiota Related to Inflammatory Responses in Patients With Huntington's Disease". Frontiers in Immunology. 11: 603594. doi:10.3389/fimmu.2020.603594. PMC 7933529. PMID 33679692.
^{[non-primary source needed]}Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. (August 2019). "Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease". Neuron. 103 (4): 627–641.e7. doi:10.1016/j.neuron.2019.05.035. PMC 6706297. PMID 31255487.
Jankovic J (April 2008). "Parkinson's disease: clinical features and diagnosis". Journal of Neurology, Neurosurgery, and Psychiatry. 79 (4): 368–376. doi:10.1136/jnnp.2007.131045. PMID 18344392. Archived from the original on 19 August 2015.
Armstrong MJ, Okun MS (February 2020). "Diagnosis and Treatment of Parkinson Disease: A Review". JAMA. 323 (6): 548–560. doi:10.1001/jama.2019.22360. PMID 32044947. S2CID 211079287.
Poewe W, Wenning G (November 2002). "The differential diagnosis of Parkinson's disease". European Journal of Neurology. 9 (Suppl 3): 23–30. doi:10.1046/j.1468-1331.9.s3.3.x. PMID 12464118.
Gibb WR, Lees AJ (June 1988). "The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry. 51 (6): 745–752. doi:10.1136/jnnp.51.6.745. PMC 1033142. PMID 2841426.
Mustafa HI, Fessel JP, Barwise J, Shannon JR, Raj SR, Diedrich A, et al. (January 2012). "Dysautonomia: perioperative implications". Anesthesiology. 116 (1): 205–215. doi:10.1097/ALN.0b013e31823db712. PMC 3296831. PMID 22143168.
Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G (February 2016). "Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis". Neurology. 86 (6): 566–576. doi:10.1212/WNL.0000000000002350. PMID 26764028. S2CID 207110404.
Brooks DJ (April 2010). "Imaging approaches to Parkinson disease". Journal of Nuclear Medicine. 51 (4): 596–609. doi:10.2967/jnumed.108.059998. PMID 20351351.
Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP (2014). "The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T". PLOS ONE. 9 (4): e93814. Bibcode:2014PLoSO...993814S. doi:10.1371/journal.pone.0093814. PMC 3977922. PMID 24710392.
Mahlknecht P, Krismer F, Poewe W, Seppi K (April 2017). "Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease". Movement Disorders. 32 (4): 619–623. doi:10.1002/mds.26932. PMID 28151553. S2CID 7730034.
Cho SJ, Bae YJ, Kim JM, Kim D, Baik SH, Sunwoo L, et al. (March 2021). "Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis". European Radiology. 31 (3): 1268–1280. doi:10.1007/s00330-020-07240-7. PMID 32886201. S2CID 221478854.
Boonstra JT, Michielse S, Temel Y, Hoogland G, Jahanshahi A (February 2021). "Neuroimaging Detectable Differences between Parkinson's Disease Motor Subtypes: A Systematic Review". Movement Disorders Clinical Practice. 8 (2): 175–192. doi:10.1002/mdc3.13107. PMC 7853198. PMID 33553487.
Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM (2015). "The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review". EJNMMI Research. 5: 12. doi:10.1186/s13550-015-0087-1. PMC 4385258. PMID 25853018.
Greenland & Barker 2018. Greenland JC, Barker RA (2018). "Chapter 6: The Differential Diagnosis of Parkinson's Disease". In Stoker TB, Greenland JC (eds.). Parkinson's disease: Pathogenesis and Clinical Aspects. Codon Publications. pp. 109–128. doi:10.15586/codonpublications.parkinsonsdisease.2018.ch6. ISBN 978-0-9944381-6-4. PMID 30702839. S2CID 80908095.
McCann H, Stevens CH, Cartwright H, Halliday GM (January 2014). "α-Synucleinopathy phenotypes". Parkinsonism & Related Disorders. 20 (Suppl 1): S62–S67. doi:10.1016/S1353-8020(13)70017-8. hdl:1959.4/53593. PMID 24262191.
Ganguly J, Jog M (5 November 2020). "Tauopathy and Movement Disorders-Unveiling the Chameleons and Mimics". Frontiers in Neurology. 11: 599384. doi:10.3389/fneur.2020.599384. PMC 7674803. PMID 33250855.
Gupta D, Kuruvilla A (December 2011). "Vascular parkinsonism: what makes it different?". Postgraduate Medical Journal. 87 (1034): 829–836. doi:10.1136/postgradmedj-2011-130051. PMID 22121251. S2CID 29227069.
Miguel-Puga A, Villafuerte G, Salas-Pacheco J, Arias-Carrión O (22 September 2017). "Therapeutic Interventions for Vascular Parkinsonism: A Systematic Review and Meta-analysis". Frontiers in Neurology. 8: 481. doi:10.3389/fneur.2017.00481. PMC 5614922. PMID 29018399.
Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU (February 2016). "The Differential Diagnosis and Treatment of Atypical Parkinsonism". Deutsches Arzteblatt International. 113 (5): 61–69. doi:10.3238/arztebl.2016.0061. PMC 4782269. PMID 26900156.
Ahlskog JE (July 2011). "Does vigorous exercise have a neuroprotective effect in Parkinson disease?". Neurology. 77 (3): 288–294. doi:10.1212/wnl.0b013e318225ab66. PMC 3136051. PMID 21768599.
Ascherio A, Schwarzschild MA (November 2016). "The epidemiology of Parkinson's disease: risk factors and prevention". The Lancet. Neurology. 15 (12): 1257–1272. doi:10.1016/S1474-4422(16)30230-7. PMID 27751556. S2CID 19994300.
Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A (2010). "Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies". Journal of Alzheimer's Disease. 20 (Suppl 1): S221–S238. doi:10.3233/JAD-2010-091525. PMID 20182023.
de Lau LM, Breteler MM (June 2006). "Epidemiology of Parkinson's disease". The Lancet. Neurology. 5 (6): 525–535. doi:10.1016/S1474-4422(06)70471-9. PMID 16713924. S2CID 39310242.
Kalia LV, Lang AE (August 2015). "Parkinson's disease". Lancet. 386 (9996): 896–912. doi:10.1016/s0140-6736(14)61393-3. PMID 25904081. S2CID 5502904.
Gagne JJ, Power MC (March 2010). "Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis". Neurology. 74 (12): 995–1002. doi:10.1212/WNL.0b013e3181d5a4a3. PMC 2848103. PMID 20308684.
Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS (April 2019). "Emerging therapies in Parkinson disease - repurposed drugs and new approaches". Nature Reviews. Neurology. 15 (4): 204–223. doi:10.1038/s41582-019-0155-7. PMC 7758837. PMID 30867588.
Connolly BS, Lang AE (30 April 2014). "Pharmacological treatment of Parkinson disease: a review". JAMA. 311 (16): 1670–1683. doi:10.1001/jama.2014.3654. PMID 24756517. S2CID 205058847.
Zhang J, Tan LC (2016). "Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist". Current Neuropharmacology. 14 (4): 356–363. doi:10.2174/1570159X14666151208114634. PMC 4876591. PMID 26644151.
Moosa S, Martínez-Fernández R, Elias WJ, Del Alamo M, Eisenberg HM, Fishman PS (September 2019). "The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease". Movement Disorders. 34 (9): 1243–1251. doi:10.1002/mds.27779. PMID 31291491. S2CID 195879250.
Pedrosa DJ, Timmermann L (2013). "Review: management of Parkinson's disease". Neuropsychiatric Disease and Treatment (Review). 9: 321–340. doi:10.2147/NDT.S32302. PMC 3592512. PMID 23487540.
Orgeta V, McDonald KR, Poliakoff E, Hindle JV, Clare L, Leroi I (February 2020). "Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease". The Cochrane Database of Systematic Reviews. 2020 (2): CD011961. doi:10.1002/14651858.cd011961.pub2. PMC 7043362. PMID 32101639.
Oertel WH (13 March 2017). "Recent advances in treating Parkinson's disease". F1000Research (Review). 6: 260. doi:10.12688/f1000research.10100.1. PMC 5357034. PMID 28357055.
Binde et al. 2018, p. missing. Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M (September 2018). "A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease". British Journal of Clinical Pharmacology. 84 (9): 1917–1927. doi:10.1111/bcp.13651. PMC 6089809. PMID 29847694.
Aquino CC, Fox SH (January 2015). "Clinical spectrum of levodopa-induced complications". Movement Disorders. 30 (1): 80–89. doi:10.1002/mds.26125. PMID 25488260. S2CID 22301199.
Yan Z, Wang W, Tao X, Cheng W, Zuo G, Chen Z, et al. (November 2022). "High-dose versus low-dose inhaled levodopa (CVT-301) in patients with Parkinson disease for the treatment of OFF episodes: a meta-analysis of randomized controlled trials". Neurological Sciences. 43 (11): 6233–6241. doi:10.1007/s10072-022-06298-z. PMID 35907110. S2CID 251162631.
Paik J (June 2020). "Levodopa Inhalation Powder: A Review in Parkinson's Disease". Drugs. 80 (8): 821–828. doi:10.1007/s40265-020-01307-x. PMID 32319076. S2CID 216033034.
Tambasco N, Romoli M, Calabresi P (2018). "Levodopa in Parkinson's Disease: Current Status and Future Developments". Current Neuropharmacology. 16 (8): 1239–1252. doi:10.2174/1570159X15666170510143821. PMC 6187751. PMID 28494719.
Akhtar MJ, Yar MS, Grover G, Nath R (January 2020). "Neurological and psychiatric management using COMT inhibitors: A review". Bioorganic Chemistry. 94: 103418. doi:10.1016/j.bioorg.2019.103418. PMID 31708229.
Scott LJ (September 2016). "Opicapone: A Review in Parkinson's Disease". Drugs. 76 (13): 1293–1300. doi:10.1007/s40265-016-0623-y. PMID 27498199. S2CID 5787752.
Watkins P (2000). "COMT inhibitors and liver toxicity". Neurology. 55 (11 Suppl 4): S51–52, discussion S53–56. PMID 11147510.
Goldenberg MM (October 2008). "Medical management of Parkinson's disease". P & T. 33 (10): 590–606. PMC 2730785. PMID 19750042.
Samii A, Nutt JG, Ransom BR (May 2004). "Parkinson's disease". Lancet. 363 (9423): 1783–1793. doi:10.1016/S0140-6736(04)16305-8. PMID 15172778. S2CID 35364322.
Ceravolo R, Frosini D, Rossi C, Bonuccelli U (December 2009). "Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management". Parkinsonism & Related Disorders. 15 (Suppl 4): S111–S115. doi:10.1016/S1353-8020(09)70847-8. PMID 20123548.
Binde et al. 2018, p. 1924. Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M (September 2018). "A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease". British Journal of Clinical Pharmacology. 84 (9): 1917–1927. doi:10.1111/bcp.13651. PMC 6089809. PMID 29847694.
Alborghetti M, Nicoletti F (2019). "Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside". Current Neuropharmacology. 17 (9): 861–873. doi:10.2174/1570159X16666180830100754. PMC 7052841. PMID 30160213.
Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, et al. (September 2004). "Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients". BMJ. 329 (7466): 593. doi:10.1136/bmj.38184.606169.AE. PMC 516655. PMID 15310558.
Crosby N, Deane KH, Clarke CE (2003). "Amantadine in Parkinson's disease". The Cochrane Database of Systematic Reviews. 2003 (1): CD003468. doi:10.1002/14651858.CD003468. PMC 8715353. PMID 12535476.
Hasnain M, Vieweg WV, Baron MS, Beatty-Brooks M, Fernandez A, Pandurangi AK (July 2009). "Pharmacological management of psychosis in elderly patients with parkinsonism". The American Journal of Medicine. 122 (7): 614–622. doi:10.1016/j.amjmed.2009.01.025. PMID 19559160.
Elbers RG, Verhoef J, van Wegen EE, Berendse HW, Kwakkel G (October 2015). "Interventions for fatigue in Parkinson's disease". The Cochrane Database of Systematic Reviews (Review). 2015 (10): CD010925. doi:10.1002/14651858.CD010925.pub2. PMC 9240814. PMID 26447539.
Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, et al. (February 2011). "Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues". Archives of Neurology. 68 (2): 165. doi:10.1001/archneurol.2010.260. PMC 4523130. PMID 20937936.
Dallapiazza et al. 2018. Dallapiazza RF, De Vloo PD, Fomenko A, Lee DJ, Hamani C, Munhoz RP, et al. (2018). "Chapter 8: Considerations for Patient and Target Selection in Deep Brain Stimulation surgery for Parkinson's disease". In Stoker TB, Greenland JC (eds.). Parkinson's disease: Pathogenesis and Clinical Aspects. Codon Publications. doi:10.15586/codonpublications.parkinsonsdisease.2018.ch8. ISBN 978-0-9944381-6-4. PMID 30702838. S2CID 81155324.
Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, et al. (Cochrane Movement Disorders Group) (January 2023). "Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis". The Cochrane Database of Systematic Reviews. 1 (1): CD013856. doi:10.1002/14651858.CD013856.pub2. PMC 9815433. PMID 36602886.
Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL (April 2008). "The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis". Movement Disorders. 23 (5): 631–640. doi:10.1002/mds.21922. hdl:10871/17451. PMID 18181210. S2CID 3808899.
Dereli EE, Yaliman A (April 2010). "Comparison of the effects of a physiotherapist-supervised exercise programme and a self-supervised exercise programme on quality of life in patients with Parkinson's disease". Clinical Rehabilitation. 24 (4): 352–362. doi:10.1177/0269215509358933. PMID 20360152. S2CID 10947269.
Jin X, Wang L, Liu S, Zhu L, Loprinzi PD, Fan X (December 2019). "The Impact of Mind-body Exercises on Motor Function, Depressive Symptoms, and Quality of Life in Parkinson's Disease: A Systematic Review and Meta-analysis". International Journal of Environmental Research and Public Health. 17 (1): 31. doi:10.3390/ijerph17010031. PMC 6981975. PMID 31861456.
Barichella M, Cereda E, Pezzoli G (October 2009). "Major nutritional issues in the management of Parkinson's disease". Movement Disorders. 24 (13): 1881–1892. doi:10.1002/mds.22705. hdl:2434/67795. PMID 19691125. S2CID 23528416.
Ramazzina I, Bernazzoli B, Costantino C (31 March 2017). "Systematic review on strength training in Parkinson's disease: an unsolved question". Clinical Interventions in Aging. 12: 619–628. doi:10.2147/CIA.S131903. PMC 5384725. PMID 28408811.
Fox CM, Ramig LO, Ciucci MR, Sapir S, McFarland DH, Farley BG (November 2006). "The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders". Seminars in Speech and Language. 27 (4): 283–299. doi:10.1055/s-2006-955118. PMID 17117354. S2CID 260320960.
Dixon L, Duncan D, Johnson P, Kirkby L, O'Connell H, Taylor H, et al. (July 2007). "Occupational therapy for patients with Parkinson's disease". The Cochrane Database of Systematic Reviews. 2007 (3): CD002813. doi:10.1002/14651858.CD002813.pub2. PMC 6991932. PMID 17636709.
Ferrell B, Connor SR, Cordes A, Dahlin CM, Fine PG, Hutton N, et al. (June 2007). "The national agenda for quality palliative care: the National Consensus Project and the National Quality Forum". Journal of Pain and Symptom Management. 33 (6): 737–744. doi:10.1016/j.jpainsymman.2007.02.024. PMID 17531914.
Lorenzl S, Nübling G, Perrar KM, Voltz R (2013). "Palliative treatment of chronic neurologic disorders". Ethical and Legal Issues in Neurology. Handbook of Clinical Neurology. Vol. 118. Elsevier. pp. 133–139. doi:10.1016/B978-0-444-53501-6.00010-X. ISBN 978-0-444-53501-6. PMID 24182372.
Ghoche R (December 2012). "The conceptual framework of palliative care applied to advanced Parkinson's disease". Parkinsonism & Related Disorders. 18 (Suppl 3): S2–S5. doi:10.1016/j.parkreldis.2012.06.012. PMID 22771241.
Wilcox SK (January 2010). "Extending palliative care to patients with Parkinson's disease". British Journal of Hospital Medicine. 71 (1): 26–30. doi:10.12968/hmed.2010.71.1.45969. PMID 20081638.
Moens K, Higginson IJ, Harding R (October 2014). "Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review". Journal of Pain and Symptom Management. 48 (4): 660–677. doi:10.1016/j.jpainsymman.2013.11.009. PMID 24801658.
Casey G (August 2013). "Parkinson's disease: a long and difficult journey". Nursing New Zealand. 19 (7): 20–24. PMID 24195263.
Hähnel T, Raschka T, Sapienza S, Klucken J, Glaab E, Corvol JC, et al. (May 2024). "Progression subtypes in Parkinson's disease identified by a data-driven multi cohort analysis". npj Parkinson's Disease. 10 (1): 95. doi:10.1038/s41531-024-00712-3. PMC 11066039. PMID 38698004.
Poewe W (December 2006). "The natural history of Parkinson's disease". Journal of Neurology. 253 (Suppl 7): VII2–VII6. doi:10.1007/s00415-006-7002-7. PMID 17131223. S2CID 35082340.
Sveinbjornsdottir S (October 2016). "The clinical symptoms of Parkinson's disease". Journal of Neurochemistry. 139 (S1): 318–324. doi:10.1111/jnc.13691. PMID 27401947.
Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. (May 2019). "Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016". The Lancet. Neurology. 18 (5): 459–480. doi:10.1016/S1474-4422(18)30499-X. PMC 6459001. PMID 30879893.
Caballol N, Martí MJ, Tolosa E (September 2007). "Cognitive dysfunction and dementia in Parkinson disease". Movement Disorders. 22 (Suppl 17): S358–S366. doi:10.1002/mds.21677. PMID 18175397. S2CID 3229727.
Gomperts SN (April 2016). "Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia". Continuum (Review). 22 (2 Dementia): 435–463. doi:10.1212/CON.0000000000000309. PMC 5390937. PMID 27042903.
Panicker et al. 2021, pp. 1. Panicker N, Ge P, Dawson VL, Dawson TM (April 2021). "The cell biology of Parkinson's disease". The Journal of Cell Biology. 220 (4). doi:10.1083/jcb.202012095. PMC 8103423. PMID 33749710.
Binde et al. 2018, p. 1989. Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M (September 2018). "A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease". British Journal of Clinical Pharmacology. 84 (9): 1917–1927. doi:10.1111/bcp.13651. PMC 6089809. PMID 29847694.
Li G, Ma J, Cui S, He Y, Xiao Q, Liu J, et al. (31 July 2019). "Parkinson's disease in China: a forty-year growing track of bedside work". Translational Neurodegeneration. 8 (1): 22. doi:10.1186/s40035-019-0162-z. PMC 6668186. PMID 31384434.
Dorsey ER, Sherer T, Okun MS, Bloem BR (2018). "The Emerging Evidence of the Parkinson Pandemic". Journal of Parkinson's Disease. 8 (s1): S3–S8. doi:10.3233/JPD-181474. PMC 6311367. PMID 30584159.
Garcia-Ptacek S, Kramberger MG (September 2016). "Parkinson Disease and Dementia". Journal of Geriatric Psychiatry and Neurology. 29 (5): 261–270. doi:10.1177/0891988716654985. PMID 27502301. S2CID 21279235.
Lewis PA, Plun-Favreau H, Rowley M, Spillane J (March 2020). "Pierre D. and the first photographs of Parkinson's disease". Movement Disorders. 35 (3): 389–391. doi:10.1002/MDS.27965. PMC 7155099. PMID 31975439.
García Ruiz PJ (December 2004). "[Prehistory of Parkinson's disease]" [Prehistory of Parkinson's disease]. Neurologia (in Spanish). 19 (10): 735–737. PMID 15568171.. The article mistakenly refers to Job 34:19 instead of Job 33:19.
Lanska DJ (2009). "Chapter 33 the history of movement disorders". History of Neurology. Handbook of Clinical Neurology. Vol. 95. Elsevier. pp. 501–546. doi:10.1016/S0072-9752(08)02133-7. ISBN 978-0-444-52009-8. PMID 19892136.
Koehler PJ, Keyser A (September 1997). "Tremor in Latin texts of Dutch physicians: 16th-18th centuries". Movement Disorders. 12 (5): 798–806. doi:10.1002/mds.870120531. PMID 9380070. S2CID 310819.
Bereczki D (May 2010). "The description of all four cardinal signs of Parkinson's disease in a Hungarian medical text published in 1690". Parkinsonism & Related Disorders. 16 (4): 290–293. doi:10.1016/j.parkreldis.2009.11.006. PMID 19948422.
Lees AJ (September 2007). "Unresolved issues relating to the shaking palsy on the celebration of James Parkinson's 250th birthday". Movement Disorders. 22 (Suppl 17): S327–S334. doi:10.1002/mds.21684. PMID 18175393. S2CID 9471754.
Louis ED (November 1997). "The shaking palsy, the first forty-five years: a journey through the British literature". Movement Disorders. 12 (6): 1068–1072. doi:10.1002/mds.870120638. PMID 9399240. S2CID 34630080.
Fahn S (2008). "The history of dopamine and levodopa in the treatment of Parkinson's disease". Movement Disorders. 23 (Suppl 3): S497–S508. doi:10.1002/mds.22028. PMID 18781671. S2CID 45572523.
Guridi J, Lozano AM (November 1997). "A brief history of pallidotomy". Neurosurgery. 41 (5): 1169–1180, discussion 1180–1183. doi:10.1097/00006123-199711000-00029. PMID 9361073.
Hornykiewicz O (2002). "L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent". Amino Acids. 23 (1–3): 65–70. doi:10.1007/s00726-001-0111-9. PMID 12373520. S2CID 25117208.
Coffey RJ (March 2009). "Deep brain stimulation devices: a brief technical history and review". Artificial Organs. 33 (3): 208–220. doi:10.1111/j.1525-1594.2008.00620.x. PMID 18684199.
Armstrong MJ, Okun MS (November 2020). "Time for a New Image of Parkinson Disease". JAMA Neurology. 77 (11): 1345–1346. doi:10.1001/jamaneurol.2020.2412. PMID 32716484. S2CID 220796667.
Prenger MT, Madray R, Van Hedger K, Anello M, MacDonald PA (2020). "Social Symptoms of Parkinson's Disease". Parkinson's Disease. 2020: 8846544. doi:10.1155/2020/8846544. PMC 7790585. PMID 33489081.
Crooks S, Carter G, Wilson CB, Wynne L, Stark P, Doumas M, et al. (2023). "Exploring public perceptions and awareness of Parkinson's disease: A scoping review". PLOS ONE. 18 (9): e0291357. Bibcode:2023PLoSO..1891357C. doi:10.1371/journal.pone.0291357. PMC 10503766. PMID 37713383.
Findley LJ (September 2007). "The economic impact of Parkinson's disease". Parkinsonism & Related Disorders. 13 (Suppl): S8–S12. doi:10.1016/j.parkreldis.2007.06.003. PMID 17702630.
Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, et al. (2020). "Current and projected future economic burden of Parkinson's disease in the U.S". npj Parkinson's Disease. 6: 15. doi:10.1038/s41531-020-0117-1. PMC 7347582. PMID 32665974. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Jones JM (December 2004). "Great shakes: famous people with Parkinson disease". Southern Medical Journal. 97 (12): 1186–1189. doi:10.1097/01.SMJ.0000145284.79746.B3. PMID 15646755. S2CID 44340931.
Williams SS (September 2016). "The terrorist inside my husband's brain". Neurology. 87 (13): 1308–1311. doi:10.1212/WNL.0000000000003162. PMID 27672165.
Mari Z, Mestre TA (2022). "The Disease Modification Conundrum in Parkinson's Disease: Failures and Hopes". Frontiers in Aging Neuroscience. 14: 810860. doi:10.3389/fnagi.2022.810860. PMC 8920063. PMID 35296034.
McFarthing K, Rafaloff G, Baptista M, Mursaleen L, Fuest R, Wyse RK, et al. (24 May 2022). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update". Journal of Parkinson's Disease. 12 (4): 1073–1082. doi:10.3233/JPD-229002. PMC 9198738. PMID 35527571.
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. (March 2017). "Parkinson disease". Nature Reviews. Disease Primers. 3 (1): 17013. doi:10.1038/nrdp.2017.13. PMID 28332488. S2CID 11605091.
Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB (October 2019). "Update of the MDS research criteria for prodromal Parkinson's disease". Movement Disorders. 34 (10): 1464–1470. doi:10.1002/mds.27802. PMID 31412427. S2CID 199663713.
Sudhakar V, Richardson RM (January 2019). "Gene Therapy for Neurodegenerative Diseases". Neurotherapeutics. 16 (1): 166–175. doi:10.1007/s13311-018-00694-0. PMC 6361055. PMID 30542906.
Hitti FL, Yang AI, Gonzalez-Alegre P, Baltuch GH (September 2019). "Human gene therapy approaches for the treatment of Parkinson's disease: An overview of current and completed clinical trials". Parkinsonism & Related Disorders. 66: 16–24. doi:10.1016/j.parkreldis.2019.07.018. PMID 31324556. S2CID 198132349.
Volc D, Poewe W, Kutzelnigg A, Lührs P, Thun-Hohenstein C, Schneeberger A, et al. (July 2020). "Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial". The Lancet. Neurology. 19 (7): 591–600. doi:10.1016/S1474-4422(20)30136-8. PMID 32562684. S2CID 219947651.
Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, et al. (October 2018). "Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial". JAMA Neurology. 75 (10): 1206–1214. doi:10.1001/jamaneurol.2018.1487. PMC 6233845. PMID 29913017.
Parmar, Grealish & Henchcliffe 2020, pp. 103. Parmar M, Grealish S, Henchcliffe C (February 2020). "The future of stem cell therapies for Parkinson disease". Nature Reviews. Neuroscience. 21 (2): 103–115. doi:10.1038/s41583-019-0257-7. PMID 31907406.
Parmar, Grealish & Henchcliffe 2020, pp. 103–104. Parmar M, Grealish S, Henchcliffe C (February 2020). "The future of stem cell therapies for Parkinson disease". Nature Reviews. Neuroscience. 21 (2): 103–115. doi:10.1038/s41583-019-0257-7. PMID 31907406.
Parmar, Grealish & Henchcliffe 2020, pp. 106. Parmar M, Grealish S, Henchcliffe C (February 2020). "The future of stem cell therapies for Parkinson disease". Nature Reviews. Neuroscience. 21 (2): 103–115. doi:10.1038/s41583-019-0257-7. PMID 31907406.
Henchcliffe & Parmar 2018, pp. 134. Henchcliffe C, Parmar M (2018). "Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies". Journal of Parkinson's Disease. 8 (s1): S131–S137. doi:10.3233/JPD-181488. PMC 6311366. PMID 30584166.
Parmar, Grealish & Henchcliffe 2020, pp. 106, 108. Parmar M, Grealish S, Henchcliffe C (February 2020). "The future of stem cell therapies for Parkinson disease". Nature Reviews. Neuroscience. 21 (2): 103–115. doi:10.1038/s41583-019-0257-7. PMID 31907406.
Schweitzer JS, Song B, Herrington TM, Park TY, Lee N, Ko S, et al. (May 2020). "Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease". The New England Journal of Medicine. 382 (20): 1926–1932. doi:10.1056/NEJMoa1915872. PMC 7288982. PMID 32402162.
Parmar, Grealish & Henchcliffe 2020, pp. 105, 109. Parmar M, Grealish S, Henchcliffe C (February 2020). "The future of stem cell therapies for Parkinson disease". Nature Reviews. Neuroscience. 21 (2): 103–115. doi:10.1038/s41583-019-0257-7. PMID 31907406.
Henchcliffe & Parmar 2018, pp. 132. Henchcliffe C, Parmar M (2018). "Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies". Journal of Parkinson's Disease. 8 (s1): S131–S137. doi:10.3233/JPD-181488. PMC 6311366. PMID 30584166.
Jenner P (2014). "An overview of adenosine A2A receptor antagonists in Parkinson's disease". International Review of Neurobiology. 119: 71–86. doi:10.1016/B978-0-12-801022-8.00003-9. ISBN 978-0-12-801022-8. PMID 25175961.

ncbi.nlm.nih.gov

Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, et al. (7 December 2021). "Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019". Frontiers in Public Health. 9: 776847. doi:10.3389/fpubh.2021.776847. PMC 8688697. PMID 34950630.
Vertes AC, Beato MR, Sonne J, Khan Suheb MZ (June 2023). "Parkinson-Plus Syndrome". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 36256760. Retrieved 2 May 2024.
Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (March 2023). "Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction". Cell Death & Disease. 14 (3): 176. doi:10.1038/s41419-023-05672-9. PMC 9977911. PMID 36859484.
Johansen KK, Torp SH, Farrer MJ, Gustavsson EK, Aasly JO (28 June 2018). "A Case of Parkinson's Disease with No Lewy Body Pathology due to a Homozygous Exon Deletion in Parkin". Case Reports in Neurological Medicine. 2018: 6838965. doi:10.1155/2018/6838965. PMC 6046180. PMID 30050705.
Abusrair AH, Elsekaily W, Bohlega S (13 September 2022). "Tremor in Parkinson's Disease: From Pathophysiology to Advanced Therapies". Tremor and Other Hyperkinetic Movements. 12 (1): 29. doi:10.5334/tohm.712. PMC 9504742. PMID 36211804.
Bologna M, Paparella G, Fasano A, Hallett M, Berardelli A (March 2020). "Evolving concepts on bradykinesia". Brain. 143 (3): 727–750. doi:10.1093/brain/awz344. PMC 8205506. PMID 31834375.
Ferreira-Sánchez MD, Moreno-Verdú M, Cano-de-la-Cuerda R (February 2020). "Quantitative Measurement of Rigidity in Parkinson´s Disease: A Systematic Review". Sensors. 20 (3): 880. Bibcode:2020Senso..20..880F. doi:10.3390/s20030880. PMC 7038663. PMID 32041374.
Asci F, Falletti M, Zampogna A, Patera M, Hallett M, Rothwell J, et al. (September 2023). "Rigidity in Parkinson's disease: evidence from biomechanical and neurophysiological measures". Brain. 146 (9): 3705–3718. doi:10.1093/brain/awad114. PMC 10681667. PMID 37018058.
Becker D, Maric A, Schreiner SJ, Büchele F, Baumann CR, Waldvogel D (2 December 2022). Ahmed S (ed.). "Onset of Postural Instability in Parkinson's Disease Depends on Age rather than Disease Duration". Parkinson's Disease. 2022: 6233835. doi:10.1155/2022/6233835. PMC 9734006. PMID 36506486.
Eklund M, Nuuttila S, Joutsa J, Jaakkola E, Mäkinen E, Honkanen EA, et al. (July 2022). "Diagnostic value of micrographia in Parkinson's disease: a study with [¹²³I]FP-CIT SPECT". Journal of Neural Transmission. 129 (7): 895–904. doi:10.1007/s00702-022-02517-1. PMC 9217822. PMID 35624405.
Corrà MF, Vila-Chã N, Sardoeira A, Hansen C, Sousa AP, Reis I, et al. (January 2023). "Peripheral neuropathy in Parkinson's disease: prevalence and functional impact on gait and balance". Brain. 146 (1): 225–236. doi:10.1093/brain/awac026. PMC 9825570. PMID 35088837.
Palma JA, Kaufmann H (March 2018). "Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies". Movement Disorders. 33 (3): 372–390. doi:10.1002/mds.27344. PMC 5844369. PMID 29508455.
Warnecke T, Schäfer KH, Claus I, Del Tredici K, Jost WH (March 2022). "Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management". npj Parkinson's Disease. 8 (1): 31. doi:10.1038/s41531-022-00295-x. PMC 8948218. PMID 35332158.
Han MN, Finkelstein DI, McQuade RM, Diwakarla S (January 2022). "Gastrointestinal Dysfunction in Parkinson's Disease: Current and Potential Therapeutics". Journal of Personalized Medicine. 12 (2): 144. doi:10.3390/jpm12020144. PMC 8875119. PMID 35207632.
Skjærbæk C, Knudsen K, Horsager J, Borghammer P (January 2021). "Gastrointestinal Dysfunction in Parkinson's Disease". Journal of Clinical Medicine. 10 (3): 493. doi:10.3390/jcm10030493. PMC 7866791. PMID 33572547.
Palma JA, Kaufmann H (February 2020). "Orthostatic Hypotension in Parkinson Disease". Clinics in Geriatric Medicine. 36 (1): 53–67. doi:10.1016/j.cger.2019.09.002. PMC 7029426. PMID 31733702.
Hinkle JT, Perepezko K, Gonzalez LL, Mills KA, Pontone GM (January 2021). "Apathy and Anxiety in De Novo Parkinson's Disease Predict the Severity of Motor Complications". Movement Disorders Clinical Practice. 8 (1): 76–84. doi:10.1002/mdc3.13117. PMC 7780944. PMID 33426161.
Macías-García P, Rashid-López R, Cruz-Gómez ÁJ, Lozano-Soto E, Sanmartino F, Espinosa-Rosso R, et al. (9 May 2022). Aasly J (ed.). "Neuropsychiatric Symptoms in Clinically Defined Parkinson's Disease: An Updated Review of Literature". Behavioural Neurology. 2022: 1213393. doi:10.1155/2022/1213393. PMC 9110237. PMID 35586201.
Weintraub D, Mamikonyan E (September 2019). "The Neuropsychiatry of Parkinson Disease: A Perfect Storm". The American Journal of Geriatric Psychiatry. 27 (9): 998–1018. doi:10.1016/j.jagp.2019.03.002. PMC 7015280. PMID 31006550.
Zhang S, Ma Y (September 2022). "Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms". World Journal of Psychiatry. 12 (9): 1127–1140. doi:10.5498/wjp.v12.i9.1127. PMC 9521528. PMID 36186499.
Pahwa R, Isaacson SH, Small GW, Torres-Yaghi Y, Pagan F, Sabbagh M (December 2022). "Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel". Neurology and Therapy. 11 (4): 1571–1582. doi:10.1007/s40120-022-00388-y. PMC 9362468. PMID 35906500.
Gonzalez-Latapi P, Bayram E, Litvan I, Marras C (May 2021). "Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors". Behavioral Sciences. 11 (5): 74. doi:10.3390/bs11050074. PMC 8152515. PMID 34068064.
Bollu PC, Sahota P (2017). "Sleep and Parkinson Disease". Missouri Medicine. 114 (5): 381–386. PMC 6140184. PMID 30228640.
Dodet P, Houot M, Leu-Semenescu S, Corvol JC, Lehéricy S, Mangone G, et al. (February 2024). "Sleep disorders in Parkinson's disease, an early and multiple problem". npj Parkinson's Disease. 10 (1): 46. doi:10.1038/s41531-024-00642-0. PMC 10904863. PMID 38424131.
Almikhlafi MA (January 2024). "A review of the gastrointestinal, olfactory, and skin abnormalities in patients with Parkinson's disease". Neurosciences. 29 (1): 4–9. doi:10.17712/nsj.2024.1.20230062 (inactive 2 May 2024). PMC 10827020. PMID 38195133.{{cite journal}}: CS1 maint: DOI inactive as of May 2024 (link)
Coleman C, Martin I (16 December 2022). "Unraveling Parkinson's Disease Neurodegeneration: Does Aging Hold the Clues?". Journal of Parkinson's Disease. 12 (8): 2321–2338. doi:10.3233/JPD-223363. PMC 9837701. PMID 36278358.
De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER (2022). "Preventing Parkinson's Disease: An Environmental Agenda". Journal of Parkinson's Disease. 12 (1): 45–68. doi:10.3233/JPD-212922. PMC 8842749. PMID 34719434. S2CID 240235393.
Rose KN, Schwarzschild MA, Gomperts SN (February 2024). "Clearing the Smoke: What Protects Smokers from Parkinson's Disease?". Movement Disorders. 39 (2): 267–272. doi:10.1002/mds.29707. PMC 10923097. PMID 38226487.
Farrow SL, Gokuladhas S, Schierding W, Pudjihartono M, Perry JK, Cooper AA, et al. (February 2024). "Identification of 27 allele-specific regulatory variants in Parkinson's disease using a massively parallel reporter assay". npj Parkinson's Disease. 10 (1): 44. doi:10.1038/s41531-024-00659-5. PMC 10899198. PMID 38413607.
Smith L, Schapira AH (April 2022). "GBA Variants and Parkinson Disease: Mechanisms and Treatments". Cells. 11 (8): 1261. doi:10.3390/cells11081261. PMC 9029385. PMID 35455941.
Santos-Lobato BL (April 2024). "Towards a methodological uniformization of environmental risk studies in Parkinson's disease". npj Parkinson's Disease. 10 (1): 86. doi:10.1038/s41531-024-00709-y. PMC 11024193. PMID 38632283.
Torrey EF, Simmons W (16 September 2023). "Mercury and Parkinson's Disease: Promising Leads, but Research Is Needed". Parkinson's Disease. 2023: 4709322. doi:10.1155/2023/4709322. PMC 10517869. PMID 37744289.
Zhao Y, Ray A, Portengen L, Vermeulen R, Peters S (July 2023). "Metal Exposure and Risk of Parkinson Disease: A Systematic Review and Meta-Analysis". American Journal of Epidemiology. 192 (7): 1207–1223. doi:10.1093/aje/kwad082. PMC 10326611. PMID 37022311.
Dorsey ER, Zafar M, Lettenberger SE, Pawlik ME, Kinel D, Frissen M, et al. (2023). "Trichloroethylene: An Invisible Cause of Parkinson's Disease?". Journal of Parkinson's Disease. 13 (2): 203–218. doi:10.3233/JPD-225047. PMC 10041423. PMID 36938742.
Kaya I, Nilsson A, Luptáková D, He Y, Vallianatou T, Bjärterot P, et al. (July 2023). "Spatial lipidomics reveals brain region-specific changes of sulfatides in an experimental MPTP Parkinson's disease primate model". npj Parkinson's Disease. 9 (1): 118. doi:10.1038/s41531-023-00558-1. PMC 10372136. PMID 37495571.
Delic V, Beck KD, Pang KC, Citron BA (April 2020). "Biological links between traumatic brain injury and Parkinson's disease". Acta Neuropathologica Communications. 8 (1): 45. doi:10.1186/s40478-020-00924-7. PMC 7137235. PMID 32264976.
Koros C, Simitsi AM, Bougea A, Papagiannakis N, Antonelou R, Pachi I, et al. (July 2023). "Double Trouble: Association of Malignant Melanoma with Sporadic and Genetic Forms of Parkinson's Disease and Asymptomatic Carriers of Related Genes: A Brief Report". Medicina. 59 (8): 1360. doi:10.3390/medicina59081360. PMC 10456316. PMID 37629650.
Fazlollahi A, Zahmatyar M, Alizadeh H, Noori M, Jafari N, Nejadghaderi SA, et al. (October 2022). "Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis". BMC Neurology. 22 (1): 383. doi:10.1186/s12883-022-02874-0. PMC 9552480. PMID 36221048.
Nyholm D, Hellström PM (2 February 2021). "Effects of Helicobacter pylori on Levodopa Pharmacokinetics". Journal of Parkinson's Disease. 11 (1): 61–69. doi:10.3233/JPD-202298. PMC 7990449. PMID 33164946.
Zhou ZD, Yi LX, Wang DQ, Lim TM, Tan EK (September 2023). "Role of dopamine in the pathophysiology of Parkinson's disease". Translational Neurodegeneration. 12 (1): 44. doi:10.1186/s40035-023-00378-6. PMC 10506345. PMID 37718439.
Schulz-Schaeffer WJ (August 2010). "The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia". Acta Neuropathologica. 120 (2): 131–143. doi:10.1007/s00401-010-0711-0. PMC 2892607. PMID 20563819.
Lai SW, Lin CH, Lin HF, Lin CL, Lin CC, Liao KF (February 2017). "Herpes zoster correlates with increased risk of Parkinson's disease in older people: A population-based cohort study in Taiwan". Medicine. 96 (7): e6075. doi:10.1097/MD.0000000000006075. PMC 5319504. PMID 28207515.
Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, et al. (May 2014). "Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes". Science. 344 (6183): 519–523. Bibcode:2014Sci...344..519R. doi:10.1126/science.1249547. PMC 4910825. PMID 24786080.
Du G, Dong W, Yang Q, Yu X, Ma J, Gu W, et al. (2020). "Altered Gut Microbiota Related to Inflammatory Responses in Patients With Huntington's Disease". Frontiers in Immunology. 11: 603594. doi:10.3389/fimmu.2020.603594. PMC 7933529. PMID 33679692.
^{[non-primary source needed]}Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. (August 2019). "Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease". Neuron. 103 (4): 627–641.e7. doi:10.1016/j.neuron.2019.05.035. PMC 6706297. PMID 31255487.
Gibb WR, Lees AJ (June 1988). "The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry. 51 (6): 745–752. doi:10.1136/jnnp.51.6.745. PMC 1033142. PMID 2841426.
Mustafa HI, Fessel JP, Barwise J, Shannon JR, Raj SR, Diedrich A, et al. (January 2012). "Dysautonomia: perioperative implications". Anesthesiology. 116 (1): 205–215. doi:10.1097/ALN.0b013e31823db712. PMC 3296831. PMID 22143168.
Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP (2014). "The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T". PLOS ONE. 9 (4): e93814. Bibcode:2014PLoSO...993814S. doi:10.1371/journal.pone.0093814. PMC 3977922. PMID 24710392.
Boonstra JT, Michielse S, Temel Y, Hoogland G, Jahanshahi A (February 2021). "Neuroimaging Detectable Differences between Parkinson's Disease Motor Subtypes: A Systematic Review". Movement Disorders Clinical Practice. 8 (2): 175–192. doi:10.1002/mdc3.13107. PMC 7853198. PMID 33553487.
Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM (2015). "The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review". EJNMMI Research. 5: 12. doi:10.1186/s13550-015-0087-1. PMC 4385258. PMID 25853018.
Ganguly J, Jog M (5 November 2020). "Tauopathy and Movement Disorders-Unveiling the Chameleons and Mimics". Frontiers in Neurology. 11: 599384. doi:10.3389/fneur.2020.599384. PMC 7674803. PMID 33250855.
Miguel-Puga A, Villafuerte G, Salas-Pacheco J, Arias-Carrión O (22 September 2017). "Therapeutic Interventions for Vascular Parkinsonism: A Systematic Review and Meta-analysis". Frontiers in Neurology. 8: 481. doi:10.3389/fneur.2017.00481. PMC 5614922. PMID 29018399.
Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU (February 2016). "The Differential Diagnosis and Treatment of Atypical Parkinsonism". Deutsches Arzteblatt International. 113 (5): 61–69. doi:10.3238/arztebl.2016.0061. PMC 4782269. PMID 26900156.
Ahlskog JE (July 2011). "Does vigorous exercise have a neuroprotective effect in Parkinson disease?". Neurology. 77 (3): 288–294. doi:10.1212/wnl.0b013e318225ab66. PMC 3136051. PMID 21768599.
Gagne JJ, Power MC (March 2010). "Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis". Neurology. 74 (12): 995–1002. doi:10.1212/WNL.0b013e3181d5a4a3. PMC 2848103. PMID 20308684.
Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS (April 2019). "Emerging therapies in Parkinson disease - repurposed drugs and new approaches". Nature Reviews. Neurology. 15 (4): 204–223. doi:10.1038/s41582-019-0155-7. PMC 7758837. PMID 30867588.
Zhang J, Tan LC (2016). "Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist". Current Neuropharmacology. 14 (4): 356–363. doi:10.2174/1570159X14666151208114634. PMC 4876591. PMID 26644151.
Pedrosa DJ, Timmermann L (2013). "Review: management of Parkinson's disease". Neuropsychiatric Disease and Treatment (Review). 9: 321–340. doi:10.2147/NDT.S32302. PMC 3592512. PMID 23487540.
Orgeta V, McDonald KR, Poliakoff E, Hindle JV, Clare L, Leroi I (February 2020). "Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease". The Cochrane Database of Systematic Reviews. 2020 (2): CD011961. doi:10.1002/14651858.cd011961.pub2. PMC 7043362. PMID 32101639.
Oertel WH (13 March 2017). "Recent advances in treating Parkinson's disease". F1000Research (Review). 6: 260. doi:10.12688/f1000research.10100.1. PMC 5357034. PMID 28357055.
Binde et al. 2018, p. missing. Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M (September 2018). "A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease". British Journal of Clinical Pharmacology. 84 (9): 1917–1927. doi:10.1111/bcp.13651. PMC 6089809. PMID 29847694.
Tambasco N, Romoli M, Calabresi P (2018). "Levodopa in Parkinson's Disease: Current Status and Future Developments". Current Neuropharmacology. 16 (8): 1239–1252. doi:10.2174/1570159X15666170510143821. PMC 6187751. PMID 28494719.
Goldenberg MM (October 2008). "Medical management of Parkinson's disease". P & T. 33 (10): 590–606. PMC 2730785. PMID 19750042.
Binde et al. 2018, p. 1924. Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M (September 2018). "A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease". British Journal of Clinical Pharmacology. 84 (9): 1917–1927. doi:10.1111/bcp.13651. PMC 6089809. PMID 29847694.
Alborghetti M, Nicoletti F (2019). "Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside". Current Neuropharmacology. 17 (9): 861–873. doi:10.2174/1570159X16666180830100754. PMC 7052841. PMID 30160213.
Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, et al. (September 2004). "Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients". BMJ. 329 (7466): 593. doi:10.1136/bmj.38184.606169.AE. PMC 516655. PMID 15310558.
Crosby N, Deane KH, Clarke CE (2003). "Amantadine in Parkinson's disease". The Cochrane Database of Systematic Reviews. 2003 (1): CD003468. doi:10.1002/14651858.CD003468. PMC 8715353. PMID 12535476.
Elbers RG, Verhoef J, van Wegen EE, Berendse HW, Kwakkel G (October 2015). "Interventions for fatigue in Parkinson's disease". The Cochrane Database of Systematic Reviews (Review). 2015 (10): CD010925. doi:10.1002/14651858.CD010925.pub2. PMC 9240814. PMID 26447539.
Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, et al. (February 2011). "Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues". Archives of Neurology. 68 (2): 165. doi:10.1001/archneurol.2010.260. PMC 4523130. PMID 20937936.
Dallapiazza et al. 2018. Dallapiazza RF, De Vloo PD, Fomenko A, Lee DJ, Hamani C, Munhoz RP, et al. (2018). "Chapter 8: Considerations for Patient and Target Selection in Deep Brain Stimulation surgery for Parkinson's disease". In Stoker TB, Greenland JC (eds.). Parkinson's disease: Pathogenesis and Clinical Aspects. Codon Publications. doi:10.15586/codonpublications.parkinsonsdisease.2018.ch8. ISBN 978-0-9944381-6-4. PMID 30702838. S2CID 81155324.
Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, et al. (Cochrane Movement Disorders Group) (January 2023). "Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis". The Cochrane Database of Systematic Reviews. 1 (1): CD013856. doi:10.1002/14651858.CD013856.pub2. PMC 9815433. PMID 36602886.
Jin X, Wang L, Liu S, Zhu L, Loprinzi PD, Fan X (December 2019). "The Impact of Mind-body Exercises on Motor Function, Depressive Symptoms, and Quality of Life in Parkinson's Disease: A Systematic Review and Meta-analysis". International Journal of Environmental Research and Public Health. 17 (1): 31. doi:10.3390/ijerph17010031. PMC 6981975. PMID 31861456.
Ramazzina I, Bernazzoli B, Costantino C (31 March 2017). "Systematic review on strength training in Parkinson's disease: an unsolved question". Clinical Interventions in Aging. 12: 619–628. doi:10.2147/CIA.S131903. PMC 5384725. PMID 28408811.
Dixon L, Duncan D, Johnson P, Kirkby L, O'Connell H, Taylor H, et al. (July 2007). "Occupational therapy for patients with Parkinson's disease". The Cochrane Database of Systematic Reviews. 2007 (3): CD002813. doi:10.1002/14651858.CD002813.pub2. PMC 6991932. PMID 17636709.
Hähnel T, Raschka T, Sapienza S, Klucken J, Glaab E, Corvol JC, et al. (May 2024). "Progression subtypes in Parkinson's disease identified by a data-driven multi cohort analysis". npj Parkinson's Disease. 10 (1): 95. doi:10.1038/s41531-024-00712-3. PMC 11066039. PMID 38698004.
Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. (May 2019). "Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016". The Lancet. Neurology. 18 (5): 459–480. doi:10.1016/S1474-4422(18)30499-X. PMC 6459001. PMID 30879893.
Gomperts SN (April 2016). "Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia". Continuum (Review). 22 (2 Dementia): 435–463. doi:10.1212/CON.0000000000000309. PMC 5390937. PMID 27042903.
Panicker et al. 2021, pp. 1. Panicker N, Ge P, Dawson VL, Dawson TM (April 2021). "The cell biology of Parkinson's disease". The Journal of Cell Biology. 220 (4). doi:10.1083/jcb.202012095. PMC 8103423. PMID 33749710.
Binde et al. 2018, p. 1989. Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M (September 2018). "A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease". British Journal of Clinical Pharmacology. 84 (9): 1917–1927. doi:10.1111/bcp.13651. PMC 6089809. PMID 29847694.
Li G, Ma J, Cui S, He Y, Xiao Q, Liu J, et al. (31 July 2019). "Parkinson's disease in China: a forty-year growing track of bedside work". Translational Neurodegeneration. 8 (1): 22. doi:10.1186/s40035-019-0162-z. PMC 6668186. PMID 31384434.
Dorsey ER, Sherer T, Okun MS, Bloem BR (2018). "The Emerging Evidence of the Parkinson Pandemic". Journal of Parkinson's Disease. 8 (s1): S3–S8. doi:10.3233/JPD-181474. PMC 6311367. PMID 30584159.
Lewis PA, Plun-Favreau H, Rowley M, Spillane J (March 2020). "Pierre D. and the first photographs of Parkinson's disease". Movement Disorders. 35 (3): 389–391. doi:10.1002/MDS.27965. PMC 7155099. PMID 31975439.
Prenger MT, Madray R, Van Hedger K, Anello M, MacDonald PA (2020). "Social Symptoms of Parkinson's Disease". Parkinson's Disease. 2020: 8846544. doi:10.1155/2020/8846544. PMC 7790585. PMID 33489081.
Crooks S, Carter G, Wilson CB, Wynne L, Stark P, Doumas M, et al. (2023). "Exploring public perceptions and awareness of Parkinson's disease: A scoping review". PLOS ONE. 18 (9): e0291357. Bibcode:2023PLoSO..1891357C. doi:10.1371/journal.pone.0291357. PMC 10503766. PMID 37713383.
Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, et al. (2020). "Current and projected future economic burden of Parkinson's disease in the U.S". npj Parkinson's Disease. 6: 15. doi:10.1038/s41531-020-0117-1. PMC 7347582. PMID 32665974. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Mari Z, Mestre TA (2022). "The Disease Modification Conundrum in Parkinson's Disease: Failures and Hopes". Frontiers in Aging Neuroscience. 14: 810860. doi:10.3389/fnagi.2022.810860. PMC 8920063. PMID 35296034.
McFarthing K, Rafaloff G, Baptista M, Mursaleen L, Fuest R, Wyse RK, et al. (24 May 2022). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update". Journal of Parkinson's Disease. 12 (4): 1073–1082. doi:10.3233/JPD-229002. PMC 9198738. PMID 35527571.
Sudhakar V, Richardson RM (January 2019). "Gene Therapy for Neurodegenerative Diseases". Neurotherapeutics. 16 (1): 166–175. doi:10.1007/s13311-018-00694-0. PMC 6361055. PMID 30542906.
Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, et al. (October 2018). "Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial". JAMA Neurology. 75 (10): 1206–1214. doi:10.1001/jamaneurol.2018.1487. PMC 6233845. PMID 29913017.
Henchcliffe & Parmar 2018, pp. 134. Henchcliffe C, Parmar M (2018). "Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies". Journal of Parkinson's Disease. 8 (s1): S131–S137. doi:10.3233/JPD-181488. PMC 6311366. PMID 30584166.
Schweitzer JS, Song B, Herrington TM, Park TY, Lee N, Ko S, et al. (May 2020). "Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease". The New England Journal of Medicine. 382 (20): 1926–1932. doi:10.1056/NEJMoa1915872. PMC 7288982. PMID 32402162.
Henchcliffe & Parmar 2018, pp. 132. Henchcliffe C, Parmar M (2018). "Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies". Journal of Parkinson's Disease. 8 (s1): S131–S137. doi:10.3233/JPD-181488. PMC 6311366. PMID 30584166.

ninds.nih.gov

"Parkinson's Disease Information Page". NINDS. 30 June 2016. Retrieved 18 July 2016.

nytimes.com

Tauber P (17 July 1988). "Ali: Still Magic". The New York Times. Archived from the original on 17 November 2016. Retrieved 2 April 2011.
Macur J (26 March 2008). "For the Phinney Family, a Dream and a Challenge". The New York Times. Archived from the original on 6 November 2014. Retrieved 25 May 2013. About 1.5 million Americans have received a diagnosis of Parkinson's disease, but only 5 to 10 percent learn of it before age 40, according to the National Parkinson Foundation. Davis Phinney was among the few.

parkinson.org

"Tremor". Parkinson's Foundation. Retrieved 28 April 2024.
"Facial Masking". Parkinson's Foundation. Retrieved 28 April 2024.
"Rigidity". Parkinson's Foundation. Retrieved 28 April 2024.
"Postural Instability (Balance & Falls)". Parkinson's Foundation. Retrieved 29 April 2024.
"National Parkinson Foundation – Mission". Archived from the original on 21 December 2010. Retrieved 28 March 2011.
"Notable Figures with Parkinson's". Parkinson's Foundation. Retrieved 22 November 2023.

pdf.org

"About PDF". Parkinson's Disease Foundation. Archived from the original on 15 May 2011. Retrieved 24 July 2016.

researchgate.net

García Ruiz PJ (December 2004). "[Prehistory of Parkinson's disease]" [Prehistory of Parkinson's disease]. Neurologia (in Spanish). 19 (10): 735–737. PMID 15568171.. The article mistakenly refers to Job 34:19 instead of Job 33:19.

scientificamerican.com

Robbins R (30 September 2016). "How Lewy body dementia gripped Robin Williams". Scientific American. Retrieved 9 April 2018.

scmp.com

"Parkinson's experts sent to help Deng". South China Morning Post. Hong Kong. 26 January 1995. Archived from the original on 30 November 2023. Retrieved 30 November 2023.

semanticscholar.org

api.semanticscholar.org

Kon T, Tomiyama M, Wakabayashi K (February 2020). "Neuropathology of Lewy body disease: Clinicopathological crosstalk between typical and atypical cases". Neuropathology. 40 (1): 30–39. doi:10.1111/neup.12597. PMID 31498507. S2CID 201983865.
De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER (2022). "Preventing Parkinson's Disease: An Environmental Agenda". Journal of Parkinson's Disease. 12 (1): 45–68. doi:10.3233/JPD-212922. PMC 8842749. PMID 34719434. S2CID 240235393.
Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C, et al. (2008). "Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease". Movement Disorders. 23 (Suppl 3): S548–S559. doi:10.1002/mds.22062. PMID 18781672. S2CID 13186083.
Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, et al. (June 2010). "Missing pieces in the Parkinson's disease puzzle". Nature Medicine. 16 (6): 653–661. doi:10.1038/nm.2165. PMID 20495568. S2CID 3146438.
Li X, Sundquist J, Sundquist K (23 December 2011). "Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden". Neuro-Degenerative Diseases. 10 (1–4): 277–284. doi:10.1159/000333222. PMID 22205172. S2CID 39874367.
Tan EK, Chao YX, West A, Chan LL, Poewe W, Jankovic J (June 2020). "Parkinson disease and the immune system - associations, mechanisms and therapeutics". Nature Reviews. Neurology. 16 (6): 303–318. doi:10.1038/s41582-020-0344-4. PMID 32332985. S2CID 216111568.
Armstrong MJ, Okun MS (February 2020). "Diagnosis and Treatment of Parkinson Disease: A Review". JAMA. 323 (6): 548–560. doi:10.1001/jama.2019.22360. PMID 32044947. S2CID 211079287.
Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G (February 2016). "Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis". Neurology. 86 (6): 566–576. doi:10.1212/WNL.0000000000002350. PMID 26764028. S2CID 207110404.
Mahlknecht P, Krismer F, Poewe W, Seppi K (April 2017). "Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease". Movement Disorders. 32 (4): 619–623. doi:10.1002/mds.26932. PMID 28151553. S2CID 7730034.
Cho SJ, Bae YJ, Kim JM, Kim D, Baik SH, Sunwoo L, et al. (March 2021). "Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis". European Radiology. 31 (3): 1268–1280. doi:10.1007/s00330-020-07240-7. PMID 32886201. S2CID 221478854.
Greenland & Barker 2018. Greenland JC, Barker RA (2018). "Chapter 6: The Differential Diagnosis of Parkinson's Disease". In Stoker TB, Greenland JC (eds.). Parkinson's disease: Pathogenesis and Clinical Aspects. Codon Publications. pp. 109–128. doi:10.15586/codonpublications.parkinsonsdisease.2018.ch6. ISBN 978-0-9944381-6-4. PMID 30702839. S2CID 80908095.
Gupta D, Kuruvilla A (December 2011). "Vascular parkinsonism: what makes it different?". Postgraduate Medical Journal. 87 (1034): 829–836. doi:10.1136/postgradmedj-2011-130051. PMID 22121251. S2CID 29227069.
Ascherio A, Schwarzschild MA (November 2016). "The epidemiology of Parkinson's disease: risk factors and prevention". The Lancet. Neurology. 15 (12): 1257–1272. doi:10.1016/S1474-4422(16)30230-7. PMID 27751556. S2CID 19994300.
de Lau LM, Breteler MM (June 2006). "Epidemiology of Parkinson's disease". The Lancet. Neurology. 5 (6): 525–535. doi:10.1016/S1474-4422(06)70471-9. PMID 16713924. S2CID 39310242.
Kalia LV, Lang AE (August 2015). "Parkinson's disease". Lancet. 386 (9996): 896–912. doi:10.1016/s0140-6736(14)61393-3. PMID 25904081. S2CID 5502904.
Connolly BS, Lang AE (30 April 2014). "Pharmacological treatment of Parkinson disease: a review". JAMA. 311 (16): 1670–1683. doi:10.1001/jama.2014.3654. PMID 24756517. S2CID 205058847.
Moosa S, Martínez-Fernández R, Elias WJ, Del Alamo M, Eisenberg HM, Fishman PS (September 2019). "The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease". Movement Disorders. 34 (9): 1243–1251. doi:10.1002/mds.27779. PMID 31291491. S2CID 195879250.
Dissanayaka 2021, pp. 139–156. Dissanayaka NN (8 March 2021). "Chapter 9: Anxiety in Parkinson's Disease". In Byrne GJ, Panchana NA (eds.). Anxiety in Older People: Clinical and Research Perspectives. Cambridge University Press. pp. 139–156. doi:10.1017/9781139087469.009. ISBN 978-1-108-82636-5. S2CID 87250745.
Aquino CC, Fox SH (January 2015). "Clinical spectrum of levodopa-induced complications". Movement Disorders. 30 (1): 80–89. doi:10.1002/mds.26125. PMID 25488260. S2CID 22301199.
Yan Z, Wang W, Tao X, Cheng W, Zuo G, Chen Z, et al. (November 2022). "High-dose versus low-dose inhaled levodopa (CVT-301) in patients with Parkinson disease for the treatment of OFF episodes: a meta-analysis of randomized controlled trials". Neurological Sciences. 43 (11): 6233–6241. doi:10.1007/s10072-022-06298-z. PMID 35907110. S2CID 251162631.
Paik J (June 2020). "Levodopa Inhalation Powder: A Review in Parkinson's Disease". Drugs. 80 (8): 821–828. doi:10.1007/s40265-020-01307-x. PMID 32319076. S2CID 216033034.
Scott LJ (September 2016). "Opicapone: A Review in Parkinson's Disease". Drugs. 76 (13): 1293–1300. doi:10.1007/s40265-016-0623-y. PMID 27498199. S2CID 5787752.
Samii A, Nutt JG, Ransom BR (May 2004). "Parkinson's disease". Lancet. 363 (9423): 1783–1793. doi:10.1016/S0140-6736(04)16305-8. PMID 15172778. S2CID 35364322.
Dallapiazza et al. 2018. Dallapiazza RF, De Vloo PD, Fomenko A, Lee DJ, Hamani C, Munhoz RP, et al. (2018). "Chapter 8: Considerations for Patient and Target Selection in Deep Brain Stimulation surgery for Parkinson's disease". In Stoker TB, Greenland JC (eds.). Parkinson's disease: Pathogenesis and Clinical Aspects. Codon Publications. doi:10.15586/codonpublications.parkinsonsdisease.2018.ch8. ISBN 978-0-9944381-6-4. PMID 30702838. S2CID 81155324.
Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL (April 2008). "The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis". Movement Disorders. 23 (5): 631–640. doi:10.1002/mds.21922. hdl:10871/17451. PMID 18181210. S2CID 3808899.
Dereli EE, Yaliman A (April 2010). "Comparison of the effects of a physiotherapist-supervised exercise programme and a self-supervised exercise programme on quality of life in patients with Parkinson's disease". Clinical Rehabilitation. 24 (4): 352–362. doi:10.1177/0269215509358933. PMID 20360152. S2CID 10947269.
Barichella M, Cereda E, Pezzoli G (October 2009). "Major nutritional issues in the management of Parkinson's disease". Movement Disorders. 24 (13): 1881–1892. doi:10.1002/mds.22705. hdl:2434/67795. PMID 19691125. S2CID 23528416.
Fox CM, Ramig LO, Ciucci MR, Sapir S, McFarland DH, Farley BG (November 2006). "The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders". Seminars in Speech and Language. 27 (4): 283–299. doi:10.1055/s-2006-955118. PMID 17117354. S2CID 260320960.
Poewe W (December 2006). "The natural history of Parkinson's disease". Journal of Neurology. 253 (Suppl 7): VII2–VII6. doi:10.1007/s00415-006-7002-7. PMID 17131223. S2CID 35082340.
Caballol N, Martí MJ, Tolosa E (September 2007). "Cognitive dysfunction and dementia in Parkinson disease". Movement Disorders. 22 (Suppl 17): S358–S366. doi:10.1002/mds.21677. PMID 18175397. S2CID 3229727.
Garcia-Ptacek S, Kramberger MG (September 2016). "Parkinson Disease and Dementia". Journal of Geriatric Psychiatry and Neurology. 29 (5): 261–270. doi:10.1177/0891988716654985. PMID 27502301. S2CID 21279235.
Koehler PJ, Keyser A (September 1997). "Tremor in Latin texts of Dutch physicians: 16th-18th centuries". Movement Disorders. 12 (5): 798–806. doi:10.1002/mds.870120531. PMID 9380070. S2CID 310819.
Lees AJ (September 2007). "Unresolved issues relating to the shaking palsy on the celebration of James Parkinson's 250th birthday". Movement Disorders. 22 (Suppl 17): S327–S334. doi:10.1002/mds.21684. PMID 18175393. S2CID 9471754.
Louis ED (November 1997). "The shaking palsy, the first forty-five years: a journey through the British literature". Movement Disorders. 12 (6): 1068–1072. doi:10.1002/mds.870120638. PMID 9399240. S2CID 34630080.
Fahn S (2008). "The history of dopamine and levodopa in the treatment of Parkinson's disease". Movement Disorders. 23 (Suppl 3): S497–S508. doi:10.1002/mds.22028. PMID 18781671. S2CID 45572523.
Hornykiewicz O (2002). "L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent". Amino Acids. 23 (1–3): 65–70. doi:10.1007/s00726-001-0111-9. PMID 12373520. S2CID 25117208.
Armstrong MJ, Okun MS (November 2020). "Time for a New Image of Parkinson Disease". JAMA Neurology. 77 (11): 1345–1346. doi:10.1001/jamaneurol.2020.2412. PMID 32716484. S2CID 220796667.
Matthews W (April 2006). "Ali's Fighting Spirit". Neurology Now. 2 (2): 10–23. doi:10.1097/01222928-200602020-00004. S2CID 181104230.
Jones JM (December 2004). "Great shakes: famous people with Parkinson disease". Southern Medical Journal. 97 (12): 1186–1189. doi:10.1097/01.SMJ.0000145284.79746.B3. PMID 15646755. S2CID 44340931.
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. (March 2017). "Parkinson disease". Nature Reviews. Disease Primers. 3 (1): 17013. doi:10.1038/nrdp.2017.13. PMID 28332488. S2CID 11605091.
Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB (October 2019). "Update of the MDS research criteria for prodromal Parkinson's disease". Movement Disorders. 34 (10): 1464–1470. doi:10.1002/mds.27802. PMID 31412427. S2CID 199663713.
Hitti FL, Yang AI, Gonzalez-Alegre P, Baltuch GH (September 2019). "Human gene therapy approaches for the treatment of Parkinson's disease: An overview of current and completed clinical trials". Parkinsonism & Related Disorders. 66: 16–24. doi:10.1016/j.parkreldis.2019.07.018. PMID 31324556. S2CID 198132349.
Volc D, Poewe W, Kutzelnigg A, Lührs P, Thun-Hohenstein C, Schneeberger A, et al. (July 2020). "Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial". The Lancet. Neurology. 19 (7): 591–600. doi:10.1016/S1474-4422(20)30136-8. PMID 32562684. S2CID 219947651.

theconversation.com

McKeith IG (6 November 2015). "Robin Williams had dementia with Lewy bodies – so, what is it and why has it been eclipsed by Alzheimer's?". The Conversation. Archived from the original on 4 November 2016. Retrieved 6 April 2018.

theguardian.com

Brockes E (11 April 2009). "'It's the gift that keeps on taking'". The Guardian. London. Archived from the original on 8 October 2013. Retrieved 25 October 2010.

time.com

"Education: Joy in Giving". Time. 18 January 1960. Archived from the original on 20 February 2011. Retrieved 2 April 2011.
Davis P (3 May 2007). "Michael J. Fox". The Time 100. New York: Time. Archived from the original on 25 April 2011. Retrieved 2 April 2011.

ufl.edu

mbi.ufl.edu

"UF neurologists create a new image of Parkinson disease". McKnight Brain Institute, University of Florida. 27 July 2020. Retrieved 17 November 2023.

ukm.my

spaj.ukm.my

Jaaffar FS, Aizuddin AN, Ahmad N (21 February 2024). "Environmental Risk Factors of Parkinson's Disease: A Scoping Review". International Journal of Public Health Research. 14 (1): 1823–1831. ISSN 2232-0245.

unsw.edu.au

unsworks.unsw.edu.au

McCann H, Stevens CH, Cartwright H, Halliday GM (January 2014). "α-Synucleinopathy phenotypes". Parkinsonism & Related Disorders. 20 (Suppl 1): S62–S67. doi:10.1016/S1353-8020(13)70017-8. hdl:1959.4/53593. PMID 24262191.

washingtonpost.com

Mufson S (20 February 1997). "China's Deng Xiaoping Is Dead at 92". The Washington Post. Retrieved 30 November 2023.

web.archive.org

Jankovic J (April 2008). "Parkinson's disease: clinical features and diagnosis". Journal of Neurology, Neurosurgery, and Psychiatry. 79 (4): 368–376. doi:10.1136/jnnp.2007.131045. PMID 18344392. Archived from the original on 19 August 2015.
The National Collaborating Centre for Chronic Conditions, ed. (2006). "Diagnosing Parkinson's Disease". Parkinson's Disease. London: Royal College of Physicians. pp. 29–47. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.
The National Collaborating Centre for Chronic Conditions, ed. (2006). "Symptomatic pharmacological therapy in Parkinson's disease". Parkinson's Disease (Technical report). London: Royal College of Physicians. pp. 59–100. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010. Retrieved 14 March 2023.
The National Collaborating Centre for Chronic Conditions, ed. (2006). "Palliative care in Parkinson's disease". Parkinson's Disease. London: Royal College of Physicians. pp. 147–151. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.
"Tasmar 100 mg Tablets – Summary of Product Characteristics (SmPC) – (emc)". www.medicines.org.uk. Archived from the original on 6 August 2020. Retrieved 7 January 2021.
The National Collaborating Centre for Chronic Conditions, ed. (2006). "Non-motor features of Parkinson's disease". Parkinson's Disease. London: Royal College of Physicians. pp. 113–133. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.
The National Collaborating Centre for Chronic Conditions, ed. (2006). "Surgery for Parkinson's disease". Parkinson's Disease. London: Royal College of Physicians. pp. 101–111. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.
The National Collaborating Centre for Chronic Conditions, ed. (2006). "Other key interventions". Parkinson's Disease. London: Royal College of Physicians. pp. 135–146. ISBN 978-1-86016-283-1. Archived from the original on 24 September 2010.
Parkinson J (1817). An Essay on the Shaking Palsy. London: Whittingham and Roland for Sherwood, Neely, and Jones. Archived from the original on 24 September 2015.
"Parkinson's – 'the shaking palsy'". GlaxoSmithKline. 1 April 2009. Archived from the original on 14 May 2011.
"National Parkinson Foundation – Mission". Archived from the original on 21 December 2010. Retrieved 28 March 2011.
"Education: Joy in Giving". Time. 18 January 1960. Archived from the original on 20 February 2011. Retrieved 2 April 2011.
"About PDF". Parkinson's Disease Foundation. Archived from the original on 15 May 2011. Retrieved 24 July 2016.
"American Parkinson Disease Association: Home". American Parkinson Disease Association. Archived from the original on 10 May 2012. Retrieved 9 August 2010.
"About EPDA". European Parkinson's Disease Association. 2010. Archived from the original on 15 August 2010. Retrieved 9 August 2010.
Davis P (3 May 2007). "Michael J. Fox". The Time 100. New York: Time. Archived from the original on 25 April 2011. Retrieved 2 April 2011.
Brockes E (11 April 2009). "'It's the gift that keeps on taking'". The Guardian. London. Archived from the original on 8 October 2013. Retrieved 25 October 2010.
Brey RL (April 2006). "Muhammad Ali's Message: Keep Moving Forward". Neurology Now. 2 (2): 8. doi:10.1097/01222928-200602020-00003. Archived from the original on 27 September 2011. Retrieved 22 August 2020.
Tauber P (17 July 1988). "Ali: Still Magic". The New York Times. Archived from the original on 17 November 2016. Retrieved 2 April 2011.
Macur J (26 March 2008). "For the Phinney Family, a Dream and a Challenge". The New York Times. Archived from the original on 6 November 2014. Retrieved 25 May 2013. About 1.5 million Americans have received a diagnosis of Parkinson's disease, but only 5 to 10 percent learn of it before age 40, according to the National Parkinson Foundation. Davis Phinney was among the few.
"Who We Are". Davis Phinney Foundation. Archived from the original on 11 January 2012. Retrieved 18 January 2012.
"Parkinson's experts sent to help Deng". South China Morning Post. Hong Kong. 26 January 1995. Archived from the original on 30 November 2023. Retrieved 30 November 2023.
Gallman S (4 November 2015). "Robin Williams' widow speaks: Depression didn't kill my husband". CNN. Archived from the original on 4 November 2015. Retrieved 6 April 2018.
"LBDA Clarifies Autopsy Report on Comedian, Robin Williams". Lewy Body Dementia Association. 10 November 2014. Archived from the original on 12 August 2020. Retrieved 19 April 2018.
McKeith IG (6 November 2015). "Robin Williams had dementia with Lewy bodies – so, what is it and why has it been eclipsed by Alzheimer's?". The Conversation. Archived from the original on 4 November 2016. Retrieved 6 April 2018.
"World's first Parkinson's vaccine is trialled". New Scientist. London. 7 June 2012. Archived from the original on 23 April 2015.

who.int

icd.who.int

"ICD-11 for Mortality and Morbidity Statistics". icd.who.int. Retrieved 27 April 2024.

worldcat.org

Connie T, Aderinola TB, Ong TS, Goh MKO, Erfianto B, Purnama B (12 December 2022). "Pose-Based Gait Analysis for Diagnosis of Parkinson's Disease". Algorithms. 15 (12). MDPI AG: 474. doi:10.3390/a15120474. ISSN 1999-4893.
Jaaffar FS, Aizuddin AN, Ahmad N (21 February 2024). "Environmental Risk Factors of Parkinson's Disease: A Scoping Review". International Journal of Public Health Research. 14 (1): 1823–1831. ISSN 2232-0245.
Salles PA, Tirapegui JM, Chaná-Cuevas P (22 March 2024). "Genetics of Parkinson's disease: Dominant forms and GBA". Neurology Perspectives. 4 (3): 100153. doi:10.1016/j.neurop.2024.100153. ISSN 2667-0496.
Smida K, Albedah MA, Rashid RF, Al-Qawasmi AR (23 October 2022). "Molecular dynamics method for targeting α-synuclein aggregation induced Parkinson's disease using boron nitride nanostructures". Engineering Analysis with Boundary Elements. 146: 89–95. doi:10.1016/j.enganabound.2022.10.016. ISSN 0955-7997.
Gamborg M, Hvid LG, Dalgas U, Langeskov-Christensen M (3 October 2021). "Review for "Parkinson's disease and intensive exercise therapy — An updated systematic review and meta-analysis"". Acta Neurologica Scandinavica. doi:10.1111/ane.13579/v1/review2. ISSN 1600-0404.
Olanow CW, Stocchi F, Lang AE (2011). "The non-motor and non-dopaminergic features of PD". Parkinson's Disease: Non-Motor and Non-Dopaminergic Features. Wiley-Blackwell. ISBN 978-1-4051-9185-2. OCLC 743205140.
Maria N (2017). Levodopa pharmacokinetics – from stomach to brain: A study on patients with Parkinson's disease. Linköping: Linköping University Electronic Press. p. 10. ISBN 978-91-7685-557-7. OCLC 993068595.

zenodo.org

Samii A, Nutt JG, Ransom BR (May 2004). "Parkinson's disease". Lancet. 363 (9423): 1783–1793. doi:10.1016/S0140-6736(04)16305-8. PMID 15172778. S2CID 35364322.